Home

Overview of Non-VKA Monitoring Module

image

Contents

1. e eeeeeeeeeee eere eene enne nnn 136 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Contents List of Message Templates iced rre aia ARENAS 138 Adding a New Message Template eese enne nennen nnn nnn nnn nnn nnn n cc 139 12 Adding Editing a Message Event eleseeeeeeeeeee eene nennen nnne nnn nnne nennen 139 Stot Message EVO Eed 141 Adding a New M ssage Ae 142 13 Setting up a Cessation Rea rt 142 List of Cessation RE aS ONS seess EE 144 Choosing Cessation Reason Application Area eeeeee eric eeseeeeeeeee eene n nennt nar rr rr nnns nnn nn nnn 145 Cessation Reason d EE 146 14 E COMME I E IIT 146 19 RIK CMG CG 148 SEVERITY OF RISK SEHN Oaa Eaa a ea 149 RISK ge 149 PISK CMS A dd 150 15 Adding A New CITING ir EEN mut oreu Rae EUM UE E EEkE 151 BEEE a e c 153 Adding Clinic De E 154 Adding Slot Temi plates en 155 New Slot Tem plate POr Mii 156 Saved A erent cinaes 157 Clinic Adjustment FORM aic coo eai ania ic erae Co aaa 158 Saved Clinic Adjustment POMO ur a a a aa a a aa a 159 Creating the Daly e 160 clinice P 1 e 161 17 Adding a Health ALUMNO Eesen 161 LAST OF Me o 162 Adding a New Health Authority ege EE EE Ee 163 18 Adding Editing Organisation Types
2. DAWN l ntico aged on as Support 45 with user profe Tap Grade Patient view Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary w Message center everiby Manage Messages and pass messages by d severis Type e RiskClass Reports Custom reports ApplicationArea amp DiagnosisGroup amp Diagnosisstage A mc Settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 1 1 List of Patient Allergies Allergy EETITENENENNNMITTI frayfever dR FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 1 2 Adding a New Patient Allergy Allergy New record Description SY roucanaddan Inllse x DK MATTE TUS 9 2 Adding Editing Blood Groups If you need to add an blood group for a patient that does not exist in the standard list new blood groups can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreement License_MaxActivePatientlount Frontpage E3Normal Tables Lookup tables E3 Anticoagulation Tables e Allergy Bloodsroup amp Diagnosis Drug Druginteraction EthnicOrigin Event HCProFessionalTvpe JournalltemT
3. LocalSettings Patient Weight None selected v O EnableCustomizedWeekPatterns Getting Started Workflow DAWN WORKING THROUGH THE SYSTEM Before starting to dose patients and use the DAWN system in a live situation we need to set up several sections first This configures the DAWN system to your specific needs so that patients can be monitored quickly and effectively and all the information logged against them is correct e the patient is booked into the correct clinic at the correct time and has the correct referring GP and consultant details In order to initially start using the system you can go through some of these steps in order FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Read the Safety Read the Customer Add a new Health Authority Section of the Manual Obligations Section of This groups the the Manual Organisations within your system Add a new Organisation We need to add these so that healthcare professionals and clinics can belong to a specific organisation Add a new Organisation Ward Add a new Patient Group You can optionally add patient groups in order to Add a new User Profile We need to add user profiles so that different users can define particular subsets of patients E P P access specific parts of the system within the system Add a new Healthcare Professional We Add a new Clinic
4. eeeeeeeeeee eere eene ene nennen nnn 163 List or Organisation TY DOS eege EE 165 Adding a New Organisation Type c aii 166 19 AdGING a New Org ANS MON s ego serge a A EEE 166 LIST OF OF GANIS ANIONS E A secede E E A E A A E E E 168 New Orgams ation FOTI EEN 169 20 Adding a New Organisation Ward Opttonal see RENE REENEN ENEE eene 169 EISTO Wall CN 171 New Ward EE E 172 21 Adding a New Patient Group Optional eeeseeeeeeeeee eene nennen nennen 172 List of Patient EE 174 NEW Patient Group Orin ii a 175 22 Adding a New User e UE 175 Viewing and Editing Existing User Profiles ences eene enne nennen nnn nnn n nnn n nnn nnn nn nnn n nnn 177 Adding a New User e UE 178 23 Adding Editing Healthcare Professional Types eeeeeeeee eere 181 List of Healthcare Professional Types ecce eiae oee ice ee e cero ec oou e ce ro ce ceo geed oeatr Cer EE ad 182 Adding a New Healthcare Professional Type neeeeeeeeeeeeeeeeeeeeenn enne nennen cc 183 24 Adding a New Healthcare Professional eeeeeeeeeeeeeee rere enne 183 List of Healthcare Professionals e one cie euece oec Coa caa cu eec ceux eee eco cres eege 185 Adding Healthcare Professional Details eeeeeeeeeeeeeeeeeeee eene eene nennen nnn nnn n nnn n nnn nn nnn nhanh annt 186 Adding Hea
5. 9 6 Adding Editing Procedures If you need to add a procedure for a patient that does not exist in the standard list new procedures can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 KR License_MaxActivePatientCount Fou are current fogged an ar Support 45 att Leer prone Top Grade Frontpage d Normal Tables TOT PP SLookup tables D ya AAA E Anticoagulation Tables A A FRAMEWORF e Allergy Bloodiroup Diagnosis io Druginteraction Ethnicorigin e Event HCProfessionalType amp JournalltemType e LetterTemplate OrganisationT p e Procedure Anticoaqulati Patient view C Add edit or dose a patient List view Daily routines attendance and non attendance Diary Consult the diary e Risk Message center O Severity Manage messages and pass messages by phone di Severity Type RiskClass Reports Application rea custom reports DiagnosisGroup amp DiagnosisStage Settings Discipline Modify your personal settings MeetingTvpe E DrugDoseUnits Current location Far printing Select a location ze Drugburationtinits FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh JI 9 6 1 List of Procedures Procedure Description Wamlevel PreWarmDuration PostWarnDuration Re D
6. Caption EventType b Template Patient message Send no message v Mext fKin message Send no message wi GP message Send no message w Consultant message Send no message Ke EE s Keep informed level Mane selecked v one selected HCProfessionalType ClinicYiewTableMessageEy dl Inl se PrinterPaperType 9 13 Setting up a Cessation Reason Different cessation reasons can be set up within DAWN so that this can chosen within the patient s treatment plan Please note once a cessation reason has been added into DAWN the cessation reason will then become a mandatory field to fill in within the patient s treatment plan FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreement bel Welcome License_MaxActivePatientCour Fou are currently logged an ap Support 35 ssl usar proble Tap Grade Frontpage 1 Normal Tables pa SCH Lookup tables D ya m DA 6 Anticoagulation Tables AAPIE Allergy i BloodGroup Diagnosis SOS 1 7 Patient view Druginteraction ax add edit or dose a patient amp EthnicOrigin Event i HCProFessionalTvpe JournalltemType e LetterTemplate List view Daily ro Attendance and non attend rem Diary Organisation Type q Consult the diary Procedure amp Risk Message center e Severity Manage messages and p
7. These lists are for guidance only and are not exhaustive Please use your clinical judgement before decision making Click for more details on Xarelto Other contraindications Clinically significant active bleeding Creatinine clearance 15ml min BR Hepatic impairment or liver disease expected to have any impact on survival E Hypersensitivity to tablet excipients or galactise Paediatric Patient E Pregnancy and breastfeeding Prosthetic Heart Valve intolerance Haemorrhagic Risks I Active ulcerative gastrointestinal disease l Bronchiectasis or history of pulmonary bleeding Congenital or acquired coagulation disorder intraspinal or intracerebral vascular abr alil Recent brain spinal or ophthalmological surgery Recent intracranial or intracerebral haemorrhage Uncontrolled severe arterial hypertension vascular retinopathy ese lists are for guidance only re not exhaustive Please use your clinical judgement befo ision making These lists are for quidance only and are not exhaustive Please use your clinical judgement before decision makin Click for more details on Xarelto CHADS score None selected e C Congestive heart failure 1 H Hypertension or treated hypertension 1 A Ageolder than 75 years 1 D Diabetes mellitus 1 5 2 Previous stroke or transient ischaemic attack FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1
8. Hope Nuala 56346346 52 05 02 2013 Patient Perfect 324234343434 107 11 03 2013 NOAC Clinic Iffla Lennie 57457964 62 30 04 2013 pl ee E Patient Test 324325555 58 08 05 2013 08 05 Default dinic Overdi Set Tor comple i ij Dooley Roderick 345235235425 62 15 05 2013 Sched To PEE Patient Test 324325555 58 15 05 2013 Warfarin ClinicSched TT a Scheduled Dabigat Patient Perfect 324234343434 107 15 05 2013 14 15 Age Y A Overdue New treatment En di Balloon Horace 12045204 62 13 05 2013 NOAC Clinic Scheduled Grumble Greta 5468756541 14 05 2013 15 10 NOAC Clinic Overdue Rivarox Overdue stopped treatment plan Change Charlie C23123123 58 30 01 2015 Overdue Dabigat Scheduled active treatment plan Age Appointment Time Ctinic Summary Regime The list of patients may be filtered by date of next follow up clinic location risk class patient group diagnosis Click on the filters on the left of the list view screen to tailor the list you wish to view The Patient Search and Reports screens also provide searches on your DAWN database for patients on different anticoagulants Overview page Detailed Workflow page Back to Workflows in DAWN page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 5 2 Integrated non VKA VKA patient record The DAWN patient record accommodates treatments with warfarin and non VKAs like R
9. lt Jl SEO CENSO CHEO Gitta 1 1 1 FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 17 2 Adding a New Health Authority e License_MaxActiveratientlount Frontpage Name Normal Tables Address1 HealthAuthority Add 2 Organisation vega Ward tom HCProfessional County Clinic PostCode PatientGroup TURO LoainLog Clinic diary Fax ss MeetingTemplate Organisation gt Test ReferenceRange 0 TestGroup O TherapyTemplate e Trial DrugTemplate QuestionnaireType GeneralLookupCategory Team Lookup tables Reports HealthAuthorityStaff here are no items to display CiManagement InUse x 9 18 Adding Editing Organisation Types If you need to add a type for an organisation that does not exist in the standard list new types can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseSgreement Welcome e License MaxActivePatientoount Fou are comment fogged an ar Support 45 with usar profile Top Grade 2 Normal Tables CLINICA Lookup tables D ya CLINICAL 6 Anticoagulation Tables A RAMEVVORE e Allergy e Bloodiroup Diagnosis Crug amp Cruginteraction amp EthnicOrigin e Event e HCProfessionalType O JournalltemType amp LetterTemplate amp organisationType Proced
10. How do update DAWN when a GP s address changes Ask your database administrator to use the System menu Normal tables Organisation screen to edit the address of the surgery FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf 14 06 2013 PINO License MaxActivePatientCount Frontpage OrganisationType GP Practice Normal Tables Name HealthAuthority InUse ei 3 Organisation gt Address _R tl e TERG e HcProfessiona Address 1 _ Address 2 Cd PatientGroup e LoginLog Em e Ciicdery County _ Meeting Postcode M Telephone 0115 4442524 e Testalias Fax 7 ReferenceRange Email RE OrganisationCode How do update DAWN when a GP moves to a different surgery Ask your database administrator to use the System menu Normal tables HCProfessional screen to select a different surgery for this GP How do update DAWN when a consultant retires Ask your database administrator to use the System menu Normal tables HCProfessional screen to mark this consultant as not In use Transfer each patient to another consultant from their Treatment plan screen Altincum Tim al 45607 4 The Square r County Clinic Royal Denby Phone 015395 63091 home 17 02 2010 Indefinite Rheumatology Gold monitoring 2 weekhy 1 bk ofi active Date of referral Ss Referring GP Archibo
11. Anticoagulant Dabigatran 150 mg Twice Daily Referring GP Central Surgery Bloggs Frank Consultant Cessation Reason Side effects Or e changing the reason for anticoagulation Treatment plans for Trouble Trevor 01 01 1932 Disease area Primary Diagnosis Start date amp Anticoagulation ORTHO HIP Total hip replacement surgery 13 09 2012 06 09 2012 12 New Anticoagulation A amp FHR Atrial fibrillation nonvalrular 30 08 2012 30 09 2012 stopped For changes such as a change to clinic or duration of treatment click on Treatment plan to edit and save your changes Any changes to the treatment plan will be audited in the Audit tab on the Treatment Plan screen like this FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 2 3 PrimaryDiagnosis pTHO HIP Total hip replacer Start date 06 09 2012 EE First seen date WS Duration type Short Term Target ram Duration Weeks EN Days Regime Induction a Preferred clinic Postal Clinic St Elsewhere Sample ins Preferred time From EN until MaxPercen CessationReason Mone selected HaxInterv Status New EE ProblemPa This treatment plan ON ChangeDateTime FreldHame 05 09 2012 14 01 fkiPreferredCliniclD Default Clinic St Elsewhere Postal Clinic 06 09 2012 14 01 DurationinWeeks 12 14 back to Detailed Workflow page Stopping a non VKA
12. Drug New record drug nal Relevant interaction None selected Description DrugNotes Relevant for InUse Customization Y Y Ci In order to CustomizeDrugForPatient PatientCustomizationMNotes KN 9 5 A Adding Editing Events If you need to add an event for a patient that does not exist in the standard list new events can be added here Eel LEE ub FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 License Max amp ctivePatientCount Fou are currently fogged on ag Support 39 th usar prae Tap Grade Frontpage r Normal Tables LIMES Lookup tables DA J CLINICAL Anticoagulation Tables e B RAMEVVORK e e Allergy BloodGroup Diagnosis e Drug 7 Patient view Ca Druginteraction B EthnicOrigin is e Event edit amp HCProfessionalType amp JournalltemType e LetterTemplate OrganisationType amp Procedure Anticaaqulat Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary e Risk Message center Severity Manage messages and pass messages by phone amp Severity Type e RiskClass Reports Custom reports amp Application rea Diagnosisaroup DiagnosisStage amp Discipline MeetingTwpe e m Settings Modify your personal settings FA
13. Please use your clinical judgement before deciding on the most appropriate dose Then update the treatment plan as required Click for more details on Xarelto Dosing regime Advice Rivaroxaban 20 mg Once Recommended dose maximum recommended Daily Rivaroxaban 15 mg Once Recommended for moderate to severe renal impairment 15 49mL min creatinine Daily clearance Comments a Status Scheduled Mark as complete Information in this questionnaire is used to influence dosing and therapy decisions Please ensure all answers are accurate and complete FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 back to the Questionnaires page 5 4 Help to follow recommended SmPC Summary of Product Characteristics guidelines In this section the software alerts and dose recommendations are explained DAWN has settings for drug specific contraindications and approved dosing regimes which are used within the patient treatment plan and questionnaire to help the user adhere to the chosen guideline The settings for risks warnings and contraindications may be updated so that every review of the patient s anticoagulation is fully informed from the latest guidance DAWN will highlight the following on the questionnaire screen Contraindicated concomitant drugs or conditions including impaired renal function Warnings on inconsistency and completeness based on advanced age Dos
14. The entries on this table link a Therapeutic indication and a Risk and you should ensure that the Risk chosen is marked In Use Lookup tables C3 Anticoagulation Tables e Allergy BloodGroup Diagnosis Lookup tables e Drug Anticoagulation Tables i DrugInteraction TargetRange INR amp EthnicOrigin amp Anticoagulant Event Regime um HCProfessionalType Induction Algorithm amp JournalItemType ResultRange INR LetterTemplate ACTestAlias OrganisationType Qualifying Risk Factors Procedure d Into Th ua NB deletion of an entry for Qualifying Risk Factors may cause loss of information in any patient questionnaire not completed or unlocked for editing Therapeutic indications COPY The primary diagnosis for your patient has to be set as a valid qualifying diagnosis or therapeutic indication for the particular anticoagulant For example the settings for Dabigatran may be as shown Therapeutic Indications Anticoagulant 3 Dabigatran AFNR Atrial fibrillation nonvalvular Dabigatran 150 mg twice daily CH Dabigatran e GA ORTHO HIP Total hip replacement surgery Dabigatran 220mg once daily CH Dabigatran e gt ORTHO_KNEE Total knee replacement surgery e 5 Dabigatran once daily Add to these settings as required as new medical evidence emerges NB deleting entries on this table may result in multiple patients not getting a dose or next appointment
15. e Ensure all events have been defined correctly in the Event look up table and have been made available for use by the relevant departments e Ensure all letters have been defined correctly via message templates and have been set up to be created on the appropriate message events GO BACK TO MAIN PAGE 3 6 Safety Check List for Defining Look Up Information e Ensure all information defined in the system look up tables like the opecific Risk of Prosthetic Heart Valve has been entered and checked FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 ER 3 7 3 8 3 9 for correctness e Check that any changes you make to Lookup Anticoagulation tables do not remove important warnings or restrictions from non VKA patient records GO BACK TO MAIN PAGE Safety Check List for List View Settings List views are interactive screens showing lists of patients meeting certain criteria and who require your attention today or this week etc See Using List Views topic for more details e Check that all the required list views have been set up correctly and are available for use e For each list view check that the correct fields are displayed e For each list view check that each filter brings up the correct patients and that no patients meeting the criteria are missing GO BACK TO MAIN PAGE Safety Check List for Reports e Ensure all new altered and imported repor
16. 9 23 1 List of Healthcare Professional Types es a E oe les fus ue 7 phamsis Jas JP obs e Ofek e k bes ene JP OQ mer k Y Eonsukentnchergs Kcensukentincherge X FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 23 2 Adding a New Healthcare Professional Type Inlise x m Sr Me e EE es I LL GO atit a rim 2 qve 9 24 Adding a New Healthcare Professional Healthcare Professionals can be added to the DAWN system and can optionally be set up with user accounts to access their patients Once healthcare professionals have been added to the system they can be logged as a patients referring GP consultant etc FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 DAW Clinical version 7 8 Framework 5 LicenseA amp greerment Welcome License MaxActivePatientCnur Fou are currently fagged an as CW LTA TARR Y sth eser profe Tap Grade Frontpage DAWN Clinical Framework version 7 8 1237 Normal Tables HealthAuthority e Organisation e ward e H Professional Clinic i PatientGroup i LoginLog Clinic diary i Meeting e MeetingTemplate e Test ReferenceRange i Testaroup amp Therapy Template e Trial amp DrugTemplate i Questionnairelype
17. Technical note the table name for Interacting drugs is AnticoagulantlnteractionDrug 15 3 Specific Risks for non VKA Haemorrhagic risks thromboembolic risks and contraindicated conditions may be stored in this table for use in patient questionnaires These settings populate the questionnaire screens for haemorrhagic risks and other contraindications Anticoagulant Rivaroxaban Risk Uncontrolled severe arterial hype Risk Type Haemorrhagic risk Clinical Advice Rivaroxaban like other antithrombotic agents NB deletion of an entry for Specific Risks may cause loss of information in any patient questionnaire not completed or unlocked for editing back to Settings for New Oral Anticoagulants page Technical note the table name for Specific Risks is AnticoagulantRisk FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 15 4 Regime and Non VKA Dose Regime settings are required for each Rivaroxaban or other non VKA dose to be used in DAWN Each dosage needs to exist as a Regime a non VKA Dose and as a Permitted Regime If a new dosage or dosage frequency is approved you may add this to each of the 3 following tables as appropriate so that the settings are available in a DAWN patient record Regime n T AO e IVIIZVCLE P CAII E AUT Cw Ley EP am vum o WWW See Rivaroxaban 15 mg Once Daily Daily Active E Rivaroxaban 15 mg Twice D
18. 9 27 5 Setting Up a New Printing Location e In DAWN press the F5 key to display the menu on the left of the screen Select e Normal Tables Organisation Then select or search for the required Organisation And click on the View Details icon FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 e On the Organisation details screen select the Location tab OrganisationType o Laboratory Name Sig Hospital x Si Mame ege CH Lab room Mr Nurse Station 3 Reception Click on the Insert A Record icon to display the New Record screen e Enter a name for the new printing location and click OK The Organisation Location tab will be displayed again Click on the name of the new location to re display its details Click on the Insert A Record icon next to the Printers in this location field to display a list of available printers FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Please select a Printer For Ehe table PrinterLocation You can select more than one ikem W sdel Colour Paper 44 W sdc1 HP Business Inkjet 1200 Series Paper 44 W sdcl HP CLJ2820 PCL 6 Black white Paper 44 W sdclhp LaserJet 1320 PCL 6 Paper 44 o KA e Select the required printer and click OK or select multiple printers by holding down the shift key while clicki
19. Download as 4ML Download as Test Emal address Pe To bring up an additional menu on the DAWN front screen choose the F5 key on your keyboard or click on the Sys Menu button at the top left of the screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Reports X License green NewPatientWiza y A ey Frontpage l Normal Tables HealthAuthority e Organisation e Ward O HCProFessianal e Clinic PatientGroup amp LoginLoq amp Clinic diary e Meeting e MeetingTemplate e Test ReferenceRange e Jestroup O Therapy Template O Trial DrugTemplate e Questionnairel ype ik Senerall oct ateriotpw To close all open screens and go back to the original DAWN front screen from anywhere within the system click on the Close All Tabs button at the top left of the screen To search for a patient from anywhere within the system click on the Search button at the top left of the screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 4 1 Login Confirmation Screen s c Date of birth 1 Search Last name First name Date of birth MRN_ Status Stevenson Liza 017011922 54657565 Inactive Ferguson Stacey 0506993 2345345345 Active Pearson Paull 01001518985 213344 Active Fielding Mina 2310054945 6735674 Active Stellar Steven 017011939 457456
20. E a Search for Description c SeverityType ani Drug IT Event D Description OrderNr InUse apa od Major restan e E Ze ams 5 Jo K Moderate Hosptaization p JP ftedeat toser o P Risk See CU Ia tun KE Spa MA lc reese B Major Haen 9 ne erity i M Major Thromboembolic NA Ar 9 15 2 Risk Add or edit Risk from the Lookup tables on the F5 menu FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Proven cvericrncy romani MO beten Sala mE LInch eT psy lee TR move the ri 9 15 3 Risk Class A risk class can be chosen for a patient to indicate what their risk level is eg high risk low risk This risk class appears on the top left of the main patient screen Risk Class options can be added edited from the Lookup Tables on the F5 menu F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh RiskClass PB description LE muse 3 fiver _ E Sl JL E Sed sere JW ze 5 0 0 meer IS 9 16 Adding a New Clinic Clinics must be set up within the system so that patients can be booked into these clinics for each visit Patients can also be logged as having a particular preferred clinic You will need to set up an Organisation before cre
21. If switching from VKA is the INR still elevated Delay starting Rivaroxaban unti INR 3 0 for AFNV Date of first Rivaroxaban dose EN Measured Creatinine Clearance mL min Age at due date 58 eGFR Gender Male Serum Creatinine Tune Body Weight kg 1 23 x 140 age years x weight kg x 0 85 if female serum creatinine pmol Calculate Cockcroft Gault Crcl Cockcroft D Gault MD Nephron 16 31 41 1976 i be aware of the limitations of estimates of renal function in relation to muscle mass race and diet Other Tests A E aa OOOO OO aaa a O aaa The following lists are for guidance only and are not exhaustive Please use your clinical judgement before decision making Click for more details on Xarelto Contraindicated Drugs OTHER ANTICOAGULANT HEPARIN DABIGATRAN DRONEDARONE TRACONAZOLE KETOCONAZOLE POSACONAZOLE RITONAVIR SINTHROME WARFARIN Interacting drugs ASPIRIN CLARITHROMYCIN OTHER NSAIDs TELITHROMICIN VORICONAZOLE FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Other anticoagulant or platelet Abciximab inhibitor IN Eptifibatide Care is to be taken if patients are Prasugrel treated concomitantly with E Ticagrelor medicinal products affecting r Other haemostasis If other please give details r
22. SeneralLookupCategory e Team Lookup tables Reports Patient view p Add edit or dose a patient List view Daily routines Oke Consult the diary Message center Manage messages and pass messages by phone Reports Custom reports Settings Modify your personal settings An Organisation must be created before a Healthcare Professional can be added FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 24 1 List of Healthcare Professionals HCProfessional Search for Organisation HEProfessionalType LastName o FirstName HCProfessionalT ype i ES 11 DETHICK COURT Y 2 cr ESJS 11 DETHICK COURT ES ESI 11 DETHICK COURT ES Zi m DETHICK COURT Hole ao FK Dee by Y E Caen JONES JT dis 18 DEBAL xo en ES s besaba House mole wsevio ERS far smemo ofe mhenma ERG 21 srmeman moLise mole ifm o ERG 25 aexanerRoaD ID PAU ESS 25 ALEXANDER ROAD Pharmacist zk ERS 25 LULWORTH CRESCENT mofe ALL ZB ERG 25 LULWORTH CRESCENT mofe ISS TR z pwomes ofe Memon zn 25 LULWORTH CRESCENT y MACRAE Hw OOOO Cw Fi RAUS Down l Save Details FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 24 2 Adding Healthcare Professional Details HCProfessional New record
23. Trial DrugTemplate ib QuestonnaireT ype nm See CHADS score NB renaming or deletion of an entry for General Lookup or General Lookup Category may cause loss of information in any patient questionnaire not completed or unlocked for editing CHA2DS2 VASc Score CHA 2D52 VASc Score CH caption Value amp 0 0 e 1 GE D amp amp 5 GI e 7 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 250 Overview of Non VKA Monitoring Module index A Adding a Blood Group 112 Adding Clinic Details 154 Adding Slot Templates 155 Adding Teams 188 Adding Editing a Message Event 139 Adding Editing a Message Template 136 Adding Editing Allergies 107 Adding Editing Blood Groups 109 Adding Editing Diagnoses 112 Adding Editing Diagnosis Groups 124 Adding Editing Diagnosis Stages 127 Adding Editing Drugs 115 Adding Editing Events 118 Adding Editing Healthcare Professional Types Adding 181 Editing 181 Adding Editing Organisation Types List of Organisation Types 163 Adding Editing Procedures 121 Adding Editing WarnLevel 130 address 205 adverse events 77 B bridging 87 C cancel changes 57 75 CHADS 64 82 change dose 68 change drug 68 change 205 changing anticoagulant 86 changing type 86 clinic 205 Adding 151 Editing 151 Clinic Adjustment Form 158 Clinic Diary Slots 161 clinic 32 Clinical Framewor
24. We need to add need to add healthcare professionals so clinics so that patients cqan be booked that they are logged within the system and into the correct clinic within the can optionally access their patients system Once the above settings are all in place follow the Workflow for a Non VKA Patient 8 9 Printing from DAWN To send a letter to a patient or colleague select the patient record and click on the Letters tab at the FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 top The following dropdown menus show the letter templates loaded in your system Contact your system administrator to amend or add new templates Select a Direct Print local printer uses your local printers and any network printers you can see from your PC Select a custom message to send uses available network printers va DAWNMailer and can send messages by fax e mail phone If you use DAWN Mailer you can choose a specific location for printing on the front screen This means that if you are working in the administration office you can ensure your letters print on the administration office printer whereas if you are in a clinic room you can ensure your letters printer on the clinic room printer You can generate letters from List Views as well as automatically on scheduling authorising appointments via Message Events DAW N t FTBITIEMIDTE version 7 7 2 1155 Anton
25. e Check all drugs or medications dosages and frequencies are recorded correctly before instructing the patient GO BACK TO MAIN PAGE 3 18 Safety Check List for Warnings And Contraindication settings Initiation Questionnaire Definitions e Check all Initiation Questionnaires have been set up and checked for correctness For each questionnaire o Ensure required data may be correctly entered For example a patient s renal or hepatic function can be recorded o Ensure all the appropriate warnings to be triggered You may need to add new rules if a new warning is reported For example a patient over 80 years may not have certain doses set o Ensure all contraindications are clearly marked as such You may need to add new rules if a new contraindication is reported F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Hegime settings e Check all dose settings used in regimes to be accurate and to accommodate the required dosages Pre and Post Clinic day Checklists e We recommend that each system manager organises a pre clinic or day checklist and a Post Clinic checklist based on the above checklists GO BACK TO MAIN PAGE FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 4 Customer Obligations Customer Software Use Obligations 1 The application should be seen as an aid to the healthcare professional All
26. eGFR 48 mL min Gender Serum Creatinine 188 umol L High Body Weight 69 kg 1 23 x 140 age years x weight kg x 0 85 if female 40 mL min serum creatinine pmol L Cockcroft D Gault MD Nephron 16 31 41 1976 back to Help page 5 4 3 Warnings on inconsistency and completeness Warnings are shown for the Suggested dose on the Rivaroxaban Initiation Questionnaire for age renal impairment other warnings suggested dose Rivaroxaban is contraindicated according to information recorded above X CONTRAINDICATED Use ts not recommended On activating a treatment plan for Rivaroxaban several checks are made in the background and an error will highlight any discrepancy For example DAWN will e check that the patient has an appropriate Primary Diagnosis and highlight any not recognised as FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 4 4 therapeutic indications for the anticoagulant e check that the user has completed a Rivaroxaban Initiation Questionnaire listing drugs conditions and test results e check the dose of Rivaroxaban is advised for the Primary Diagnosis The settings for warnings may be updated as new medical evidence emerges using the Look Up Tables in DAWN back to Help page Dosing warnings Dose options are clearly presented on DAWN for the patient s indication Therapeutic Indication DVT Provoked Dosing regime A
27. height 5mm vertical align center Font Family arial helvetica sans serif font size 10pt Jastname Jheighk 5mm vertical align center Font Family arial helvetica sans seriF Fank size 12pk Firstname height Sram wertical align center Font Family arial helvetica sans serif font size 12pt dob Jheight 11mm vertical align top Font Farnily arial helvetica sans seriF Fanb size 12pt historycorment height 4mm verkical align center Font Farily arial helvetica sans serifiFont size Spt LitlehieighE Jheight 10mm vertical a center Font Farily arial helvetica sans seriF Fank size apt Date twidth 1 mm Fant fami arial helvetica 8ans zo GA d e ca SE bottom InUse i Custom FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 11 2 Adding a New Message Template Message Name Notes PrintablePatientMessage N MailMergeType DescriptionTemplate PrinterPaperType RA uM InUse CustomModule Mone selected ee ee a SS AS 9 12 Adding Editing a Message Event Message events can be created so that messages can be automatically printed faxed emailed or sent to a phone list when certain actions are carried out within the system Please test messaging settings carefully before using w
28. n HMeswe moB Bd 8 Et ba fas oE E Jr E FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 6 2 Adding a New Procedure Procedure New record WarnL evel Relevant for InUse 9 7 Adding Editing Diagnosis Groups If you need to add a diagnosis group for a diagnosis that does not exist in the standard list new diagnosis groups can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 S LicenseAgreement License MaxActivePatientiount Frontpage Welcome Fou are current fogged an ar Sunport 45 with Leer proble Tap Grade Normal Tables Lookup tables Anticoagulation Tables B e Allergy e Bloodaroup e Diagnosis e Drug Druglnteraction Ethnicorigin e Event amp HCProFessionalType amp JournalltemType O LetterTemplate amp OrganisationType Procedure amp Risk e Severity Severity Type O RiskClass Application rea e DiagnosisGroup amp DiagnosisStage e Discipline MeetingTwpe DrugDoselInits CrugDurationUnits Anticoagulat Patient view a Add edit or dose a patient List view Daily routines Attendance and nan attendance Diary Consult the diary Message center Manage message
29. the user should perform a search to ensure the patient s details have not been previously entered e Ensure all patient data including all data entered via any of the tabs on the patient screen has been entered and checked for correctness Attention should be paid to the last name first name unit number and FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 date of birth so that the patient can be uniquely identified every time Ensure all patient procedures that are entered into the system have been checked for correctness Ensure all patient events that are entered into the system have been checked for correctness Ensure all patient reminders that are entered into the system have been checked for correctness Ensure the patient has not been incorrectly marked as deceased or inactive GO BACK TO MAIN PAGE 3 12 Safety Check List for Running Clinics Monitoring Patient Results Ensure all entered laboratory results or other measurements are correct and have been entered against the correct patient with the correct test date Check any contraindicated dose and always add a comment to say why the change was made Validate each dose and next date BEFORE informing the patient If patient record books are being used adopt checks to ensure each dosage instruction label is stuck into the correct patient s record book For example print patient identifiers such a
30. 09 00 Ferguson Stacey 16 11 2009 0 00 2 00 100 Yes FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 26 Data Exchange to move settings Data exchange allows users to easily import and export items such as Dosing Regimes Message Templates List Views Custom Modules and Look up tables to and from their DAWN system without needing to involve the IT department For example the support team may create a new list view and email it to you as an XML file You would save the file to your local machine and import it into DAWN using the Data Exchange import facility The new list view would then be installed and ready for testing License_MaxActvePatientCount Fou ara curant aged an ar Support 35 wt wer profe Tap Grade Frontpage 7 Normal Tables q Lookup tables D AW N J Reports nm Management E Clinic View settings MessageManagement E Printing i I Reports een u ER amp Parameter edit or dose a patien Report List view Daily routines Attendance and non attendance amp Polar Reporting 6 Audit amp security 6 DawnInterface LA ii Diary 10 System Consult the di PolarTools p c Systemsetting amp International settings i amp DataExchange CustomModule CodedComment Message center Manage Messages and pass messages by phon Reports Custom reports Settings Modif vour per
31. 1 0 14 06 2013 e When you SAVE the coded comment the full comment will appear on the screen KZ Graph 3 Patient calle 9 15 Risk Settings There are 3 steps involved in configuring the Risk and Risk Class Set Severity for Risk Set Risk Set Risk Class License amp greement Gel Welcome 9 License MaxActivePatientCour yoy are currently logged on as Support 45 with user profile Top Grade Frontpage l Normal Tables SL les i Anticoagulation Tables AMEWOI e Allergy i Anticoagulat BloodGroup Diagnosis Drug l Patient view Q DrugInteraction ho Add edit or dose a patient EthnicOrigin e giele W List view Daily routines HCProfessionalType Attendance and non attendance JournalltemType LetterTemplate Gei Diary OrganisationType Consult the diary Procedure Risk r Message center O Severity j Manage messages and pass messages by phone O SeverityType RiskClass amp Reports Application rea Custom reports DiagnosisGroup B i i DiagnosisStage Settings Discipline modify your personal settings MeetingType DrugDoseUnits i inti i Select a location DrugDurationUnks Current location For printing FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 15 1 Severity of Risk Setting From the Lookup tables set Severity for Risk Severity
32. BP VU ee 103 Message Ce met ida 105 Configuring your system 107 Adding Edi nd BE ee TE 107 LIST OF Patient AMES ii 108 Adding a New Patient Allerg VE 109 Adding Editing Blood Groups ia 109 Listor BIOOG O OD me C ds 111 Adding a Blood Gro UD BEE 112 Adding Editing DIAGNOSE S e 112 List of Diagnoses e 114 Adding ai AV MB Wel te CC EE 115 AGGING EGUING BOIS p P 115 Listo DEUG S o EE 117 Adding a New DEUS KE 118 AGGING EGITING EVO E 118 LIS TOL ENEE eege ee 120 Adding a NEW EVe nt ec 121 Adaing Edr ng Gd te e 121 LIS eh i D UE 123 Adding a New Procedure ee a 124 Adding Editing Diagnosis Groups eoi cnica cai cidcid 124 Listor DANOS OS S 126 Adding New Diagnosis Group caian M 127 Adding Editing Diagnosis StagesS cococccnocconoconnoconcaroncaroncarnnnararnararnanarnnnarnrnararnararnararnananos 127 LIST Of Diagnosis Stages SA ce cee a aa E aA a Ee ES E E 129 Adding a New Diagnosis Stage ui A nm 130 AGGING EGIING WarnLEe VeL ce ea ag esex epos A A 130 ListofWarnLevels cionado dida 132 Adding a New EE E 133 Adding Editinj Eang atjes EE 133 LISTO PANG cle RR ELO IDOL LLL eet 135 Adding a New e UE EE 136 Adding Editing a Message Template
33. Day 1 21 A reduction of the dose from 20mg once daily to 15 mg once daily should be considered if the patient s assessed risk for bleeding outweighs the risk for recurrent DVT and PE Normal Dose Day 22 omwards NB deletion of an entry for Permitted Regimes may result in multiple patients not getting a dose or next appointment back to Settings for New Oral Anticoagulants page Technical note the table name for Permitted Regimes is Anticoagulantindic ationRegime 15 5 General Lookup Category settings for non VKA The general lookup category settings are used in some questionnaires Options available for answering questions on the questionnaire may be edited added to or deleted from this table FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreement GeneralLookupCategory License MaxActivePatientCount Frontpage Name C Normal Tables Description O HealthAuthority CodeName amp Organisation MER PME 7 GeneralLookup 155 i HCProfessional Clinic 0 qm was 0 996 in one study O PatientGroup 4 1 Risk was 3 4 in one study amp LoginLog E 2 Risk was 4 1 in one study Clinic diary 3 Risk was 5 8 in one study e Meeting B SA 4 Risk was 8 9 in one study amp MeetingTemplate 3 5 Risk was 9 196 in one study e rest Risk not known too little data 6 TestAlias T Bick nnt known tnn li
34. Faxing option in Windows XP s Printers and Faxes control panel choose otart Printers and Faxes To set up DAWNMailer 1 Create a DAWNMailer folder on the PC where you intend to run DAWNMailer 2 Copy the DAWNMailer exe and HTMLPrinter exe if present files from the Polar Studio Webroot folder to your new DAWNMailer folder 3 Double Click DAWNMailer to open the application DAWNMailer attempts to start automatically At this point you may receive an error message as DAWNMailer is not correctly configured yet 4 Click OK to close the error message The DAWNMailer dialog is displayed in Stopped mode Fill in the fields as follows Select the printer you want to use by default You can configure Dawn AC Eo print use different printers Far different messages and different locations This is convered in a separate factsheet Enter the http address For Dawn AC eo hito I DavinsSereer Dawni where Dawnserver is the name of your server do nat include the index html or palarsereerasp page name E DawnMailer Server address Use COOSYS recommended jw LDOSTS SMTP server IF you wart Dawnfailer Eo send emails enter the address of your SMTP server Default printer hp Laserjet 1320 PCL 6 wei submit Interval zec F Open your Print Station in Test Mail Dawn AC highlight the Interface key SH Identification Key and press Ctrl C bo copy ib Click into this Field and press tr
35. List view Daily routines Attendance and non attendance Ween Diary Organisation ype Consult the diary amp Procedure e Risk Message center Severity Manage messages and pass messages by phone i SeverityType amp RiskClass Reports Application rea Custom reports DiagnosisGroup amp DiagnosisStage Settings Discipline Modify your personal settings MeetingT ype E DrugDosellnits T Current location For printing Select a location ze DrugDurationLlniEs ee FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 9 8 1 List of Diagnosis Stages DiagnosisStage E ou Can Sear i 2 m co E UMS EE M LL E EE sage El Ai Search for nore JE 1 OO gt amp j RHEUMATIC HEART DISEASE Y ba B l Sd Yo Ge a F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 8 2 Adding a New Diagnosis Stage DiagnosisStage New record Diagnosis eel chosen for the stage Name OrderNr InUse eege al re IP age 9 9 Adding Editing WarnLevel If you need to add warn levels to drugs events etc that do not exist in the standard list new warn levels can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Lookup tables Anticoagulation Tables e Allergy
36. Menu then choose Management System to display the system options 2 Click on SystemSetting type Domain into the Search for Name field and click the Search button TheDefaultNetwork Domain system setting is displayed 3 Enter the name of your active directory domain in the Value field TJ 45 DAWN Clinical Software amp Internet Applications Microsoft Internet Explorer DAW N amp Ses E pull rM USEMerautneteorkdoman d Search HCPraf esional Clinic Customizations borra Mame GEN PrintStation DafaultietuorkDemain Deede com a The default domain for the network used for the automatic identification of Cinic diary users Lookup tables Reports Management MalMergo Clinic Vies settings MessageManagernent Reports EE Parameter Report Audit E security Sy sten Instant SOL Instant rip SysteniSetting International settings CodedCommerk 4 Enter ActiveDirectory in the Search for Name field and press the Search Button The SupportActiveDirectory system setting is displayed cal Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf 14 06 2013 SupportActiveDireckory 5 Change the Value to 1 to disable Active Directory support change the Value to O Updating the Healthcare Professionals Account Records 1 Choose Normal Tables HCProfessional from the System Menu to display the list of Healthcare Professionals 2 Choose the Edit form icon to the left of the appropriate Health
37. Organisation Se FirstName t InUse x Address info Account info Notes Title NationalNumber i LocalNumber DirectTelephone fs Mobile oo Ema AA DirectFax MessagingMethod E mail Can cel FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 187 9 24 3 Adding Healthcare Professional Account Info HCProfessional Organisation Bia Hospital HCProfessionalType GP LastName FirstName Initials InUse Ma Click to set new password PasswordExpirationDate 23 06 2009 Failed login count Failed login count total 0 Locked Last login date Total number of lagins UserProfile I Network arme FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 188 9 24 4 Adding Healthcare Professional Password Organisation Big Hospital hd HCProfessionalType P LastName Initials InUse xi Yes Click to reset password A random password is generated PasswordExpirationDate for your new record This can be p a used along with the user name Failed login count Failed login count total Locked Last login date Total number of logins UserProfile tn log into DAN MetworkName This password can be changed by the HC P Professional at the C DAMN login screen Click here
38. Paper Type in Message Event Setting up a New Paper Type 199 Setting up Dawn mailer Processing Messages 198 Setting up New Print Location 200 Setting up Print Station 196 Severity of Risk Setting 149 Slot Template Form 156 starting 65 stopping 70 System Workflow 102 CE treatment plan 64 U User profile Adding 175 Editing 1 75 User Profile Form NV validation checks W warnings 46 workflow 53 204 178 48 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 ER Endnotes 2 after index 4S DAWN Clinical Software 2015 Back Cover
39. Rate eGFR serum creatinine Cockcroft Gault estimation of creatinine clearance other measures may be recorded in the notes box DAWN provides a calculator for estimating renal function from serum creatinine and body weight Enter these 2 values and click on the Calculate Cockcroft Gault CrCL FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Measured Creatinine Clearance mL min Age at due date 62 eGFR ag mL min Gender Male serum Creatinine 75 pmol L Body Weight 65 kg 1 23 x 140 age years x weight kg x 0 85 if female 83 mL min serum creatinine pmol L Cockcrort D Gault MD Nephron 16 31 41 1976 Please be aware of the limitations of estimates of renal function in relation to muscle mass race and diet Click to refer to dosing quidance with renal impairment Other Blood Checks Note if you have a laboratory estimation which is less than a numeric value like lt 10 please enter the number like 10 in the Measured Creatinine Clearance eGFR or Serum Creatinine boxes Similarly for results which are reported as greater than a value like gt 220 please enter the numeric value like 220 The limits used for renal impairment are set as follows in DAWN e Severe renal failure is defined as measured creatinine clearance or estimated glomerular filtration rate or Cockcroft Gault estimation of CrCl less than 15mL min e f more than one measure of r
40. User Manual oct Version 1 0 14 06 2013 S back to Haemorrhagic Risks page 10 1 5 Wizard Screen Contact Details New Patient Wizard l 3 Referring GP 11 DETHICK COURT BISS TF Consultant 18 DEBADALE HOUSE BAKER KU Team members FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 10 1 6 New Patient Screen Age 100 EZLLZZ fibrillation nonvalvular 2 Set the status to Scheduled 3 Set the due date as appropriate Personal Treatment plans Questionnaires St Elsewhere Support Dawn Referring GP updated to 5t Elsewhere support Dawn back to Workflows in DAWN page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 217 10 2 Adding notes Sprout Russell 12 04 1951 3423434 Ed en Hon VKA 04 09 20127 gula a Uds 4 1 b ofi New St Elsewhere Support Dawn type the note here The Quick Notes are ideal for brief notes about a phone call or recent history of the patient FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 QuickNote Sprout Russell 12 04 1951 New record HCProfessional St Elsewhere Support Dawn lt Date 04 09 2012 15 43 Notes 10 3 Drug doses From the main patient screen choose the Drugs tab
41. User Manual pdf Version 1 0 14 06 2013 Non Attendees Select list vew for Rivaroxaban and the filter for Overdue AE Incomplete records Select list vew for Rivaroxaban and the filter for No next review date Listings Reports Select Reports from the front menu as required back to Detailed Workflow page 8 4 How To Navigate Around DAWN HOW TO NAVIGATE AROUND THE DAWN SCREENS There are several ways of moving through the different screens within DAWN close and save the current screen D add a new record such as a note or a diagnosis see details to delete click the bin trash can and save C de Ej To log out of the system you can use the Flag icon t Internet Explorer 15 nut opge profile Ti Oo Grade l Thu 18 06 2009 DAWN J e version 7 9 1245 i Patient view GA Add edit or dose a patient List view Daily routines Attendance and non attendance To close individual screens within DAWN you can use the black cross on that page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Internet Explorer Report 2 Time in Range Between Dates wl Show repart Download as 8ML Download as Test sil Pe To view a page you have already opened previously you can choose the screen you require from the tabs list at the left of the screen P Report Active Patient Counts by Clinic we Show report
42. V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 16 2 Adding Clinic Details Clinic New record ApplicationArea Description Organisation Localt ade InUse NE 7 Slot Templates Y l FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 KA 9 16 3 Adding Slot Templates Clinic ApplicationArea Organisation scription InUse Anticoagulation 45 Dawn Clinical Software Anticoagulation Clinic x Be anticoagulation Big Hospital Moorside Clinic x ApplicationArea Anticoagulation Description Moorside Clinic Organisation Bia Hospital Localt ade InUse EN Ges AN Ca m 3 te SlotTemplates Adjustments FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 16 4 New Slot Template Form ClinicSlotTemplate Moorside Clinic Big Hospital New record eo Start Time ed in the format HH he EndTime Max cap Reserved cap l Sun Mion Tue Wed Thu Fri Sat 025161515071 FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 157 9 16 5 Saved Slot Template Form Clinic ApplicationArea Orzanisation Description Anticoagulation 45 Dawn Clinical Sotware Anticoagulation Clinic x E anticoagulation B
43. any discrepancy an error message will indicate the problem and the user may correct the Initiation Questionnaire or the treatment plan or both and activate again Should your DAWN settings need to be updated as new medical eudence emerges please contact your system administrator Checks for non VKA treatment plans e the primary diagnosis is one known to be acceptable for the chosen drug and dose For example you may have chosen 15mg twice daily for Rivaroxaban in an AF patient If this regime is not permitted it will not be possible to complete an Initiation Questionnaire wth this combination and a treatment plan cannot be activated and a follow up cannot be scheduled DAWN AC performs 2 checks on every primary diagnosis Firstly the drug and diagnosis must be stored in your Look Up Tables as a Therapeutic indication like Rivaroxaban being acceptable as an anticoagulant in Atrial Fibrillation non valvular Secondly DAWN stores Permitted Regimes for each diagnosis So several doses such as 15mg once daily or 20mg once daily may be acceptable but 15mg twice daily may not be acceptable for Rivaroxaban in Atrial Fibrillation non valvular e the drug chosen is not a VKA anticoagulant For example you may have chosen Warfarin mixed tablets regime and marked the treatment plan as non VKA in the target range box You have selected a Mon Vitamin K Antagonist Target Range for an ih anticoagulant that is a Vitamin K Antagonist e t
44. dosage and review interval advice issued by the application must be checked by a competent healthcare professional before instructing the patient 2 The customer must have a procedure to ensure rigorous follow up of non attendees and ensure that all patients have a next test date 3 he customer must ensure that only personnel that have been adequately trained in the use of the software should operate the system 4 Prior to initial use and following any software upgrade or change to the software settings a appropriate and thorough validation exercise of the software should be completed for your local way of working before live operation Records of the results of the validation shall be maintained The validation should be authorised by the lead clinician physician A separate Test System which simulates live operation is highly recommended 5 It is vitally important that the customer site establishes a robust method of backing up and restoring their data including occasional tests of the backups through restoration Usually the backup should be done at the end of each working day If there is a lot of system activity a more frequent back up procedure should be considered 6 The customer is expected to operate best practice with regard to using pre and post clinic checklists and keeping their copy of the software up to date The product is being periodically updated with important safety and operational features If you are paying
45. got a DAWN treatment See adding a new treatment plan plan for the non VKA agent 2 Have you chosen a date or clinic filter on Adjust the filters on the left of the list view to see all the left of the non VKA list vew which patients with a non VKA treatment plan excludes this patient Q Why do I get Contraindicated warnings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 A Contraindications may be for inappropriate concurrent medications see interacting drugs or risks see haemorrhagic risks or age renal function Q The Rivaroxaban dose need to use isn t available on the DAWN screen A Your DAWN settings may need to be updated by your system manager contact support 4s DAWN com for assistance Q Where is the INR warfarin history for my patient now A view previous treatment plans using the black arrow on the patient screen and you ll see the History panel for any VKA episode of treatment Blue Brian 04 04 1946 342523555 4 Pref clinic MOAC Clinic Big Hospital T Phone 015395 63091 home E b a Target Range Non VKA 03 01 2013 Indefinite vere e RIvaroxaban 20 mg Once Daily Treatment Plan ES of2 active Risks poor complaince back to Detailed Workflow page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 7 Changing Ant
46. inhibitors A reminder to ensure INR is not inappropriately elevated if switching from a vitamin K antagonist Contraindicated conditions and Haemorrhagic Risks Records for CHA2DS2VASc and HASBLED scores Notes for planned procedures or other comments Rivaroxaban dose Once you have answered all sections click on Mark as complete at the bottom of the questionnaire F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Status Scheduled back to Integrated non VKA VKA patient record back to Detailed Workflow page back to Settings for Regime and Dose Settings page 6 1 1 Schedule an Initiation non VKA On adding an Initiation Questionnaire change the Due Date to the date you will complete the details Assessment as a Candidate for Rivaroxaban Initiation Patient Name Test Patient Date of completion 31 05 2013 11 00 Siet ui 00 24hr format HB Please check this appointment is made in your climc diary or hospital administration system NHS Number to be completed at NOAC Clinic Unit No 324325555 Status scheduled Click OK at the bottom of the Questionnaire screen to save this Initiation with the scheduled date You will find the questionnaire on the questionnaires tab for later completion FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Graph ory l Treatmen n
47. me eur Pl SE Eeselen Max ll BEE Bes ll EBIS estu meorcar gena perona gt jeermmo hes Boeson PE ES Eeer E pronen wooro LEE EDS feavewew lf pronase lb Eo pewamcwme P Bas los P ration epi Eick EN 4 TO Sos F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 19 2 New Organisation Form Organisation New record Organisation Address 1 Address Town Once the record is in LSG b County PostCode Telephone Fax Email E OrganisationCode HealthAuthority Cancel 9 20 Adding a New Organisation Ward Optional Wards can optionally be set up within the system to monitor inpatients You must have an Organisation set up within the system before creating a new Ward FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 170 e License MaxActivePatientcount Fou are currently lagged an ar Sunnort 35 th user profile Tap Grade Frontpage a Normal Tables errr Healthauthority D AWN CLINICAL amp Organisation ICK ii i FRAMEWORK ward e HCProfessional Clinic Patientaroup amp LoginLog Clinic diary Meeting e MeetingTemplate e Test amp ReferenceRange Testoroup amp TherapyTemplate A Trial amp DrugTemplate Questionnaire Type Antiz Patient view Add edi
48. mg Once Daily Referring GP 5 Consultant Cessation Reason Patient choice A If your patient does not have a current active treatment plan record on DAWN the patient may not appear on the list of scheduled FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 patients FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 12 12 1 Using List Views DAWN provides List Views to assist you with your workflows List Views are lists of patients meeting certain criteria such as patients waiting on a follow up e You can alter which patients are displayed by selecting different tabs and different filters In this way you can quickly find lists of patients needing say appointment reminders or abnormal liver function reviews e Clicking on a patient in a List View opens the patient s record so you can perform any appropriate actions such as completing a questionnaire or scheduling the next review e Closing the patient s record returns you to the list If the action you have taken means the patient no longer meets the criteria for example they no longer have an unchecked result they disappear from the list This means you are only left with the patients you still need to deal with 1 Remember there are a number of different lists for different purposes on blue tabs at the top of the screen HINT 2 If yo
49. on the OK button to return to the list of HC Professionals e e ll ad E 9 25 Adding Teams You can set up different teams within the system and assign healthcare professionals to them One or more healthcare professionals can belong to a particular team within DAWN eg Rheumatology Consultants Rheumatology Nurses Healthcare professionals can also belong to more than one team at a time You can filter List Views by team if certain teams are responsible for certain groups of patients Creating Teams also enables you to use Referrals A Referral is a request question or action with regard to a patient s therapy or test results which you may raise and refer to another team for review advice or as a request for some other action Click here to learn more about Handling Referrals To create a new Team FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 License MaxActivePatienteaunt Fou are currency jagged an ar Sunport 45 t Leer profe Top Grade Frontpage mE Normal Tables iiir At O HealthAuthority DAW N ELINICA Organisation Y FRAMEWORK e Ward E Anticoa e HCProfessional Clinic 6 PatientGroup 1 Patient view d TC add edit or dose a patient inic diary Meeting List view Daily routines e MeetingTemplate attendance and non attendance Test e ReferenceRange
50. op MSADO Lei vti bin ce Gk WebSite ES er MOM d i ED Tony WebSite 95 Dawn AC 7 E Dawn AC Te 5 23 aspnet client H images L S _ private ret a vti cm Gr ti lag Gr tj pwt Gr ti script Ep vti Ext TRE Default Web Site Properties Ei ES coe Ema kah virmb Web Site Operators Performance ISAPI Filters Home Directory Documents Director Security HTTP Headers Custom Errors Server Extensions Anonymous access and authentication control s Enable anonymous access and edit the authentication methods for this resource IP address and domain name restrictions o Grant or deny access to this resource using IP addresses or internet domain names Secure communications Require secure communications and enable client certificates when this resource Is accessed Server Certificate Wein ernticate Edit OF Cancel Apply Help 5 Deselect the Anonymous Access option and ensure the ntegrated Windows Authentication option is selected Workflows in DAWN an overview Users Daily Weekly Routines Users Daily Weekly Routines Patients for follow up today a Select list views for Sees fet vens for E E Dieser Patients starting on non VKA aan IT Use Patient search to select or add the patient to DAWN Workflow for a Patient F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban
51. si Localcode SS 2009 27 Week with appointmen Week about to be dele 4 Click here to create Last day in diary No diary available t for the next 2 of weeks to create Geeks of weeks to delete FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 16 9 Clinic Diary Slots Clinic OOO OOOO e Anticoagulation 45 Dawn Clinical Software Anticoagulation Clinic x B Anticoagulation Big Hospital Moorside Clinic xi ApplicationArea Anticoagulation si Description Organisation Big Hospital si Localtode Ce Inlise 5 xi E Create Delete Diary 2009 26 2009 27 2009 28 2009 29 2009 30 2009 31 2009 32 2009 33 21 05 2009 28 06 2009 ostorizoos 12 07 2009 19 07 2009 26 07 2009 ozfosjzo09 O9 os 2009 480 240 480 240 480 240 400 240 400 240 400 240 400 40 400 240 Week with appointments 9 17 Adding a Health Authority Health Authorities can be added into the system in order to group organisations for reporting purposes A health authority needs to be added before an organisation can be created FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreement bel Welcome License MaxActivePatientCour You are currently jogged on as Support 45 with user profile Top Grade CFro
52. time you may need to Change the dose of anticoagulant Switch to a different anticoagulant Stop the current anticoagulation record Mark the patient as inactive deceased In order to keep track of all your patients you will need to follow the daily weekly routines to check for patients overdue for follow up or not yet actively treated FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 1 Initiation Questionnaire For anticoagulants such as Rivaroxaban you may wish to always complete an Initiation Questionnaire before activating a treatment plan on DAWN You can add a Rivaroxaban Initiation Questionnaire to any patient from the Questionnaires tab Alderson Eddie 02 03 1947 D78137 12 ROCKCLIFFEGDNS WEST YORKS There is no next appointment ar active treatment to show Pref de None selected e Next appointment date TE Phone 111 222 4444 home F e are mo items to display B Wa The Due Date will default to today but you can change this if you wish If you are not ready to answer all the questions simply click OK and the details may be completed later The questions cover Indications for Rivaroxaban therapy Renal function including a calculator for Cockcroft Gault estimate of CrCl Contraindicated or Interacting drugs including other anticoagulants or platelet
53. treatment plan 1 click on Treatment plan on the Patient screen 2 select a Cessation reason mandatory only if cessation reasons are available on your DAWN database this option may not be setup for your DAWN AC system 3 click on stop 4 click on OK to the pop up box FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 For any significant change to a patient s anticoagulation such as changing drug or restarting after a period on different or no anticoagulation please stop the treatment plan and start a new treatment plan 14 06 2013 List view Patient Treatment plans X Treatment plans for Black Carmella 01 01 1942 Disease area PromaryDiapnosis Anticoagulation ORTHO KNEE Total knee replacement surgery 05 08 2012 0 Disease area n uam Anticoagulatio LLLI Seed Start date LA ShortTerm e Duration jw k Joss ois Due fo stop MT Preferred clinic None selected Preferred time From e until CessationReason Patent decision Status active MTS Admit te mme Are you sure you want to perform the action stop on record Anticoagulation 06 09 2012 You can give a short explanation in the text field below optional OK Cancel Hint add relevant details in the Notes tab as they will be easily viewed later on the Treatment Plans tab of the main patient screen like this FADEV Clinical Framew or
54. 0 14 06 2013 HASBLED score Mone selected H Hypertension 1 systolic blood pressure gt 160 mmHg or uncontrolled Renal Disease 4 A loreatinine gt 200uM or 2 6mg dL Liver Disease cirrhosis bilirubinz2xUL M AST ALT AP gt 3xULN 1 5 Stroke History 1 B Prior Major Bleeding or Predisposition to Bleeding 1 L Labile INR 1 E Age z65 years 1 Medication Usage Predisposing to Bleeding 1 p Antiplatelet agent NSAIDs Alcohol Usage History 1 Procedures planned Who will follow your use of None selected Rivaraxaban Age at due date 58 Dosing regime Advice Rivaroxaban 20 mg Once Daily Recommended dose maximum recommended Rivaroxaban 15 mg Once Daily Recommended for moderate to severe renal impairment 15 49mL min creatinine clearance suggested dose 20mg once daily with the evening meal Please use your clinical judgement before deciding an the most appropriate dose Click for more details on Xarelto Rivaroxaban Dose None selected hd Comments D Status Scheduled Mark as complete Information in this questionnaire is used to influence dosing and therapy decisions Flease ensure all answers are accurate and completa back to the Questionnaires page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 5 3 2 Rivaroxaban Follow up Questionnaire Rivaroxaban Follow Up Patient Name Horace Balloon Date of completio
55. 091 home Age 72 oz Atrial fibrillation nonvalvular Non VKA 21 12 2012 Rivaroxaban 20 mg Once Daily New of 1 back to Initiation Questionnaire page back to Risk Settings page 6 1 2 8 Haemorrhagic risks Please tick any of the risks which apply to your patient These risks are identified in prescribing guidelines as significant risks for consideration in dosing decisions for Rivaroxaban Haemorrhagic Risks Active ulcerative gastrointestinal disease Bronchiectasis or history of pulmonary bleeding Congenital or acquired coagulation disorder Intraspinal or intracerebral vascular abnormalities Recent brain spinal or ophthalmological surgery Recent intracranial or intracerebral haemorrhage Uncontrolled severe arterial hypertension LL UN I MS E MI Vascular retinopathy The list of haemorrhagic risks may be edited added to by your system administrator using the Look Up Tables called Risks and Specific Risks NB any risks identified on the Initiation Questionnaire will NOT automatically display at the top left of your patient screen see adding Risks for a new patient section or click on Risks button to add risks on the patient screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 nm Risk class Tests ordered e Pref clinic NOAC Clinic Big Hospital Phone 015395 63091 home Age 72 1 o Atrial fibrillation nonvalvul
56. 3 08 2011 15175w Sun Mon Tue Wed Thu Fri Sat rd F Da J 1 al 1S z PILLS L He SIZE PER DAE Overview page 5 3 Questionnaires for non VKA therapy management Two structured questionnaires help you record all relevant details at the time Rivaroxaban is Initiated or on Follow up reviews for your Rivaroxaban patient Initiation Questionnaire This questionnaire helps to determine whether the patient is a suitable candidate for Rivaroxaban and if so what the appropriate dose of Rivaroxaban is Follow up Questionnaire This questionnaire can be used to audit whether the patient is taking the medication correctly and whether they have experienced any problems at all The questions cover e Indications for Rivaroxaban therapy renal function including a calculator for Cockcroft Gault estimate of CrCl records for other tests Contraindicated or Interacting drugs including other anticoagulants or platelet inhibitors a reminder to ensure INR is not too high if switching from a vitamin K antagonist o Contraindicated conditions and Haemorrhagic Risks records for CHA DS VASc and HASBLED scores as appropriate notes for planned procedures or other comments o Rivaroxaban dose FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 A You should ensure that the questionnaire content is appropriate for the current recommendations drug manufacturer A Follow up
57. A Rivaroxaban User Manual pdf Version 1 0 14 06 2013 07 09 2012 T Non VKA Rivaroxaban 10mg Once Daily 03 04 2012 Treatment stopped 5topped at 07 09 2012 11 50 Anticoagulant Dabigatran 110 mg twice daily Consultant Patient decision back to Changing Anticoagulant page 7 3 Changing between VKA and non VKA In DAWN stop the treatment plan and start a new treatment plan for a change in the patient s anticoagulant Treatment plans for Stephenson Hedley 01 07 1932 ILLNM eat date Duration in weeks Status Be Anticoa gulation ATRIAL FIBRILLATION 11 04 2008 10 03 2008 stopped H Disease area tros tie ACTherapy Induction PrimaryDiagnosis ATRIAL FIBRILLATION 11 04 Maintenance Start date 10 03 2008 TE First seen date U LL Duration type Long Term 2 0 3 0 2 5 Target Treatment 5 x EE Warfarin 2 mq Strength Preferred clinic Telephone treatment plan m None selected ucc Sun Mon Tue Wed Thu Fri CessationReason Elevated etre 1 1551 12 1 Status stopped E MaxPercentDoseChange Note DAWN will prevent a change of anticoagulant within an active treatment plan back to Changing Anticoagulant page 7 4 Bridging VKA Anticoagulation with LMWH For customers who use the DAWN Anticoagulation system LMWH heparin doses may be in DAWN within a VKA treatment plan using customised dosing options FADEV Clinical Framew ork E Manual Non V KA DAWN Non
58. AZOLE The list of drugs displayed and the advice displayed on screen are defined in the Look Up Tables on your DAWN AC database Updates to the advice or additional drugs may be added to this list as required Please contact your system administrator to add new drug settings to the Interacting Drugs table back to Complete a Follow up page Other anticoagulant or platelet inhibitor It is important to record any other anticoagulant or platelet inhibitor prescribed along with Rivaroxaban even if this for a short period Other or platelet noepamab inhibitor Eptifibatide Care is to be taken if patients are Prasugrel treated conco mitantly with mi medicinal products affecting haemostasis Other If other please give details The list of drugs displayed may be added to or edited in the General Lookup Category for Anticoagulant or Platelet Inhibitors please contact your system administrator to arrange changes to the displayed options back to Complete a Follow up page Other contraindications Please tick any of the other contraindications which apply to your patient These risks are identified in prescribing guidelines as contraindications for dosing with Rivaroxaban Other contraindications Clinically significant active bleeding Creatinine clearance 15ml min Hepatic impairment or liver disease expected to have any impact on survival Hypersensitivity to tablet excipients or galactise intolera
59. Active Pye Delia 1100151943 2344 Active vetanother test 0101 98565 464646 Active Induction Patient 365 Active Microsoft Internet Explorer E FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 4 1 1 DAWN Login Screen If you want ta change your password please also fill the following two fields New pasword JO 9537 2009 45 Information Systems Ltd By logging on to this system you have been deeme eld nto the navigation pac arnings and conditions af use Inadequate Checking af Dose and Next Test Date ik njure and death e Check that all therapy instructions are appropriate before instructing a patient e nterruptions to the operations of the software e g Power failure switching of can lead to data corruption This could lead to severe or death Following any such interruption to operation increase checking vigilance e Read the Safety Section in the User Manual e Ensure backup of your database using a multiple copy schedule e By using this software the useris bound by the terms ofthe Software Licence and Maintenance agreement and Customer Obligatic document FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 5 DAWN Front Page 7 Patient view D i Add edit or dose amp patient ES List view Daily routines Attendance and no n atten
60. Adding Editing Patient Details 23 Safety Check List for Running Clinics Monitoring Patient Results 24 Safety Check List for Adding the Next Test Date Time ceres esee 25 Safety Check List for Adding Editing Patient s Details 25 Safety Check List for Adding Editing Patient Treatment Plan BUNC RTT ETERNI Eeer 25 Safety Check List for Adding Previous Treatment History 26 Safety Check List for Recording Medications and Their Doses 26 Safety Check List for Warnings And Contraindication settings 26 Customer Obligations 29 Overview of Novel Oral Anticoagulants Module 32 Non VKA MISA VIGW cioe aeos a ole e 32 Integrated non VKA VKA patient record eeeseeeeeeeee eere enne nnn 34 Questionnaires for non VKA therapy management ENEE REENEN ENEE 35 Fivaroxaban Initiation Questionnalle eege 37 Hivaroxaban Follow up Questionnaire iaa 41 Help to follow recommended SmPC Summary of Product Characteristics quidellfieS cossse cias gege ee as NEEN Oe eege CE MEE 45 Contraindicatii NS erem A 45 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf V
61. Allergy BloodGroup Click here to add Diagnosis Drug Druginteraction e EthnicOrigin i Event O HCProfessionalTvpe amp JournalltemType O LetterTemplate OrganisationT pe Procedure Risk e Severity SeverityType e PiskClass ApplicationArea DiagnosisGroup Diagnosisstage A e mc Welcome Fou are curent fogged an ar Support 35 With Leer proble Tap Grade f ee n D CLINICAI antico Patient view add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary Message center Manage messages and pass messages by el Reports Custom reports Settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 3 1 List of Diagnoses sscription or code name E Ll Search for Description T CedeName NENNEN Description __ fodeName E DiagnosisApplicationArea 3 AF CARDIOVERSION th HIS anticoagulation clinical Haematology E Rheumatology Mone selected m E Anticoagulation clinical Haematology E Rheumatology None selected bd Anticoagulation clinical Haematology Oilatie amp 3 aNEURSYM WITH EMBOLIC ER Rame t BR Rheumatology None selected m IT Anticoagulation clinical Haematology E Rheumatology Mone selected E Anticoagulation Clinical Haematology BR Rheumatoloqy US anteenospuouer
62. Cl records for other tests Contraindicated or Interacting drugs including other anticoagulants or platelet inhibitors Contraindicated conditions and Haemorrhagic Risks o records for CHADS2 and HASBLED scores notes for planned procedures or other comments Once you have answered all questions click on Mark as complete and then schedule another Follow Up for your patient See details of the Follow up Questionnaire FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 3 2 1 If you cannot answer some questions simply click OK or Save and come back later to complete the answers Mark as complete On marking the answers as complete you are confirming that DAWN can store this record display a summary on the questionnaires tab and check details against the treatment plan If you ve added some details in error Cancel your changes using Cancel or the rewind button at the top Cr DAWN If you need to delete a questionnaire completely look for the bin symbol on the questionnaires tab and of the screen save before confirming you wish to delete this record H QuestionnaireType ge Rivaroxaban Follow Up 06 06 2013 11 00 If you need to add more information or adjust the Follow up Questionnaire which is already completed 1 locate the completed questionnaire on the Questionnaires tab 2 select Unlock to edit 3 save your changes
63. Create random key e Edit the PrintStation you want to map printers to PrinterPaperType for e Scroll down to the Printers section FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Printers 2 TAS e Microsoft PS Document Writer Microsoft PS Document Writer CH Microsoft Office Document Image Writer Microsoft Office Document Image Writer Ca dede Colour Weed olor CH WWedclHP Business Inkjet 1200 Series 9 VW4dedc1 HD Business Inkjet 1200 Series WedeTHP CLJ2620 PCL 6 Black Vvhite W4edce1iHP CLJ2620 PCL 6 Black Mute SI CH Wedel bp LaserJet 1320 PCL 6 Wedel hp LaserJet 1320 PCL E WII e Select a printer from the list of printers in print station interface This will display the interface used to map a printer with printer paper type Printer dawnmailer Nunc OL Bevicetame PrinterPaperT yp Microsoft APS Document writer Microsoft APS Document Writer Microsoft Office Document Image Writer Microsoft Office Document Image Writer deeded Colour Wedel vColour Wizdcl HP Business Inkjet 1200 Series dzdc1 HP Business Inkjet 1200 Series WzdcliHP CLJ2820 PCL B Black White WdsdclHP CLJ2820 PCL B Black_vhite D m gt it Name W45de1 Colour DeviceName W4sde1 Colour RA PrinterPaperType Mone selected OrderNr None selected Inllse PrinterLocation e Select the PaperType from the drop down list e Choose Save
64. DAWN CLINICAL SOFTWARE DAWN Novel Oral Anticoagulants NonVKA Monitoring User and Safety Manual Rivaroxaban Xarelto Module FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 kee Table of Contents Part Part Il 1 Part Ill 16 17 18 Part IV Part V Foreword 10 Novel Oral Anticoagulants Module User Manual 12 How To Use the Manual 14 Hyperlinks move to the Next Gcreen ee REEN REENEN REENEN eene nennen nenne nnne nnn nnn 15 Safety Manual 17 What Safety Issues Are here RENE aa REENEN EEN REENEN REENEN En 18 Safety Check List for Adding Editing Deleting Letters Messages 19 Safety Check List for Adding Editing Deleting Patient ef ei let le 20 Safety Check List for Clinic Diary Settings eseeeeieeeeeeeeeeee eene nennen 20 Safety Check List for Defining Procedures Letters and Events 20 Safety Check List for Defining Look Up Information esee 20 Safety Check List for List View Getttngs ee EN REENEN eene nennen nennen 21 Salety Check List for HepoFts io 21 Safety Check List for Questionnaire Definitions eeeeseeseeeee eee eene 21 Safety Check List for Data and Operational Integrity eeuseee 22 Safety Check List for
65. DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 5 1 List of Events 3 EMBOLISM UNSPECIFIED always warn aol A Clinical Haematology in Rheumatology JAnticoagulation 2kouug ss warn Sol va clinical Haematology n ng event fields an Rheumatology oF anticoagulation clinical Haematology 3 BLEED LOWER GI Rheumatology BLEED o Always warn Wal RE EE Clinical Haematology Rheumatology Sol oF Anticsagulation clinical Haematology cannot be deleted i E Rheumatology Sj BRUISING UNEXPLAINED Always warn Ho PI anticoagulation clinical Haematology E Rheumatology Y CEREBRAL HAEMORRHAGE Always warn a EF anticoagulation clinical Haematology E Rheumatology always warn smo Loo anticoagulation clinical Haematology O Rheumatology L oF anticoagulation clinical Haematology E Always Warn D nt Jew button O Rheumatalagy T EXTRA ALCOHON Always wg O Anticoagulation FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh 9 5 2 Adding a New Event Event New record n event nam 2 can be added Description WarnLevel Duration Warning Relevant for
66. Diary Test roup o Consult the diary TherapyTemplate Trial Message center DrugTemplate Manage uen and pass messages by pl Questionnaire Type amp GeneralLookupCategory ES Reports Team Custam reports 5 Lookup tables Reports Settings Management D Modi your personal settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 25 1 New Team Form Team There are no records to display I ES ere to add a new 9 25 2 Choosing a New Team Organisation If your service involves several organisations certain teams might be based at or belong to certain organisations When you add a new team you can optionally select the organisation that the team belongs to To select an organisation either 1 Highlight the organisation in the list 2 Press the OK button FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 or simply double click the organisation in the list Team New record Please select a Organisation For the table Team 45 Dawn Clinical Software Morrside Hospital Big Hospital To create a team that does not belong to a specific organisation click the OK button without selecting an organisation 9 25 3 Adding a New Team 1 Enter the team name FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manua
67. FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 16 5 16 6 Interacting drugs for non VKA COPY It is possible to link an anticoagulant with a drug which has one of the following interactions if prescribed concomitantly e Contraindication e Haemorrhagic Risk e Thromboembolic Risk These settings have a notes field and the notes plus appropriate warnings will display on appropriate patient questionnaires and may prevent activation of a treatment plan see examples for contraindicated drugs and interacting drugs Interacting Drugs Anticoa gulant Dabigatran Drug IBUPROFEN Interaction Haemorrhagicrisk e Clinical Advice NB addition editing deletion of entries on this table may cause checks on important drug interactions to be missed NB deletion of an entry for Interacting Drugs may cause loss of information in any patient questionnaire not completed or unlocked for editing Technical note the table name for Interacting drugs is AnticoagulantlnteractionDrug Specific Risks for non VKA COPY Haemorrhagic risks thromboembolic risks and contraindicated conditions may be stored in this table for use in patient questionnaires These settings populate the questionnaire screens for haemorrhagic risks and other contraindications Specific Risks Anticoa gulant pabigatran Risk Organic lesion at risk of bleedin e Risk Typ
68. NB unlocking a prevous questionnaire to edit it may cause the details to be updated with subsequent changes to the patient details For example if the patient was previously on an interacting drug which was later removed from your DAWN database the drug would still be stored in the old completed questionnaire On unlocking the old questionnaire the record for this drug may no longer be available back to Detailed Workflow page Patient questions It may be useful to record patient feedback on the following questions in the Rivaroxaban Follow Up Questionnaire F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 have taken the correct dose every day No C Yes might have taken too many capsules tablets No Yes might have missed one or more doses Me Mates a have started a new medication recently C Me wes back to Complete a Follow up page 6 3 2 2 Reasons for compliance problems Please tick any of the compliance problems which apply to your patient These problems may be important in dosing decisions for Rivaroxaban Reasons for compliance problems Tc Fear of side effects Gastrointestinal Bleed Lack of information Lives alone Multiple medications Prescriptions from several doctors The list of compliance problems may be edited added to by your system administrator using the General Look Up Category Table called ComplianceR
69. SE UNSPEC VALVULAR REP MECHANICAL DOUBLE VALVULAR REPLACEMENT MECHANIC VALVULAR REPLACEMENT TISSUE VALVULAR REPLACEMENT UNSPEC VENTRICULAR SEPTAL DEFECT ORTHO HIP Total hip e Target range must be non VKA for non vitamin K antagonists e Regime choose the dose Regime None selected None selected Rivaroxaban 15 mg Once Daily Rivaroxaban 15 mg Twice Daily Rivaroxaban 20 mg Once Daily e Duration type short term requires a duration long term has no duration The treatment plan may not be activated without these selections but if you do not have the details at hand you can save the treatment plan and activate it later back to Detailed Workflow page back to FAQs page Changing a non VKA treatment plan It is strongly recommended that you stop the treatment plan and start a new treatment plan for any significant change in the patient s anticoagulation For example e Changing dose from 20mg once daily to 15mg once daily FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Treatment plans VAC Anticoagulation Start date Duration Target range Hon VKA _ Anticoagulant Rivaroxaban 20 mg Once Daily _ Referring GP Central Surgery Bloggs Frank Consultant 5 25 02 2013 Start date 09 01 2013 Duration Treatment stopped Stopped at 09 01 2013 10 19 Target range Hon VKA
70. Settings page Interacting drugs Some interacting drugs may be known to be increase the haemorrhagic risk if used along with the chosen anticoagulant See relevant published prescribing guidelines Please tick any drugs if your patient is currently prescribed this drug ASPIRIN CLARITHROMYCIN OTHER NSAIDs TELITHROMICIN VORICONAZOLE back to Initiation Questionnaire page back to Interacting Drugs Settings page Other anticoagulant or platelet inhibitor It is important to record any other anticoagulant or platelet inhibitor prescribed along with Rivaroxaban even if this for a short period F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Other anticoagulant or platelet Se Bee Abciximab inhibitor Eptifibatide Care is ta be taken if patients are Prasugrel treated concomitantly with Ticagrelor medicinal products affecting haemostasis Other If other please give details The list of drugs displayed may be added to or edited in the General Lookup Category for Anticoagulant or Platelet Inhibitors please contact your system administrator to arrange changes to the displayed options back to Initiation Questionnaire page 6 1 2 6 Switching from VKA If your patient is switching from warfarin or other vitamin K antagonist to Rivaroxaban please check the latest INR result and tick the box if it is above the recommended
71. There are several steps needed to add a new patient into the system We go through these in order below Ensure you log into the correct area of DAWN by choosing the disease area like Anticoagulation Haematology on this front screen before clicking on Patient View 7 9 Tue 04 09 2012 Version 7 9 25 1289 V Anticoagulation DAWN Patient view Sam Add edit or dose a patient Attendance and non attendanoe Diary j Consult the diary Message center Manage messages and pass messages by phone Reports Custom reports Modify your personal settings Search for your patient as they may have a record in DAWN already Selection Active patients Patients with active Treatment Plans for selected app area Show all Search for Last name First name Hosp No pceo7822e Town o County Postcode Dateofbirth DoD Language Home phone fo Mobile phone fo Work phone Next af kin name fo Next of kin Mob phone f There are no records found that match your criteria F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 q If your patient has no record on DAWN select New at the bottom of the screen to add a new record back to Starting a Non VKA Treatment Plan page 10 1 Choosing New Patient Form Patient gt G Selection Active patients Patients with active Treatmen
72. V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 P MA E D e D e D Ge Dosing i Events Sun Mon Tue Wed Thu Sun Mon Tue Wed Thu Fri Please see section on Setting up LMWH and Pentasaccharide Agents back to Changing Anticoagulant page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 1 Using the system DAWN is a web based software package installed within your network You should be able to access the system using Internet Explorer from any PC on your site and your local system administrator will set a password for you e See how to log in log in with active directory e How to navigate around DAWN e How to get started e see an overview of the workflows in DAWN Logging Into DAWN When opening up DAWN you will need to log in with your user account Take care to type your user name and password correctly using the correct combination of capital and small letters ensuring that the Caps Lock is on and off at the correct times Take care not to confuse the letter O and the number zero or the letter and the number one Username posses CrYrrT rrr rou want fo change your password please also fill the following fro fields confirm SE If you would like to change your existing password a new password can be created from this screen Before doing this hover your cursor over the blue I icon to the right of th
73. aily Daily Active l1 Rivaroxaban 20 mg Once Daily Daily Active l Warfarin 1 and 5mg in Tablets Daily with Halves Daily Active Ai Warfarin 1mg Strength in Mg Daily Avg Daily Mew Warfarin 1mg Whole Tablets in Mg Daily Avg Daily New Warfarin Img Whole Tablets in Tablets DailyAvg Daily New Warfarin 3 and 5 mq in Tablets Daily in Halves Daily New eee Description Rivaroxaban 15 mg Once Daily CodeName Rivi50D Status Active Anticoagulant Rivaroxabar Brand None selected DailyWeekly Daily DoseUnits Mg MinimumTabletPart Half a tablet Tablet 1 None selected Instruction f here are no items to display The settings are similar to VKA doses in this table except that no Instructions are required NB deletion of an entry for Regime may result in multiple patients not getting a dose or next appointment Non VKA Dose The settings for non VKA regimes link to a numeric Total Daily Dose which is stored in this table for reference Elements of the settings for a chosen regime are compared between the regime chosen in a treatment plan and in the Questionnaires and this is the basis of some of the validation checks on each patient Non V KADose n zS 15 Once Daily 15 mp ww 20 mg OnceDail 20 Each regime for which a dose check is required needs to have a setting in this table If a Rivaroxaban Initiation Questionnaire requires this dose check it will not be possible to activate a
74. aking a backup before you amend or delete settings from look up and normal tables Your procedure should also ensure that all other users refrain from making any other changes in the system until you have completed your amendments and verified they are correct This will help minimise the potential loss of data should you inadvertently delete the incorrect settings and need to restore your database e Checking the hardware for possible errors especially ensuring adequate disk space e Replacing backup media regularly media only has a set storage life e Backing up routinely at appropriate intervals and test if you are able to restore the data and programs if required e Ensuring your backup procedures are working and are appropriate for your database If your database recovery type is set to full ensure you are taking transaction log backups at regular intervals e Ensuring backup media is stored safely in a separate place from the computer system and is readily referenced e Providing adequate protection from o power failures notebook laptop battery discharge and interruptions o Staff inadvertently switching power off at the mains FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 ES e Checking for computer virus violation e Documenting and reporting software and operational problems or near misses to DAWN Clinical Software and their own management e D
75. althcare professionals and clinics can belong to a particular organisation You must have a Health Authority set up within the system before creating a new Organisation F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 167 DANT Clinical version 7 8 Framework Y License4greement Welcome License _MaxActivePatientiount Vau are curent jogged an az IOC GIRA Y wl umen profile Tap Grade Frontpage DAW Nga Clinical Framework version 7 8 173 Normal Tables Health 4uthority amp Organisation e Ward e HCProfessional Clinic e Patientsroup amp LoginLog e Clinic diary e Meeting 0 MeetingTemplate e Test ReferenceRange amp Testaroup TherapyTemplate e Trial DrugTemplate Patient view Add edit or dose a patient List view Daily routines Diary Consult the diary Message center Manage messages and pass messages by phone QuestionnaireType Reports SeneralLookupCategory Custom reports Team S Lookup tables SC b Modify your personal settings Reports EE 3 Mi fananamarnt FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 19 1 List of Organisations Organisation Selection OwnoOrganisation Show all Search for OrganisationType PH Marne MEE Address Hospital InUse Address Address Name oe Prose ene
76. amp BloodGroup Diagnosis Drug Druginteraction EthnicOrigin e Event HCProfessianalTvpe amp JournalltemType LetterTemplate Organisationl ype Procedure e Risk amp Severity amp Severity Type e RiskClass Application rea DiagnosisGroup DiagnosisStage Discipline e Meeting Type DrugDoseUnits CrugDurationUnits DrugMedium DrugYolumelnits Frequency e Warnlevel e VisitType dm es amp Anticaagulat Patient view ei add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary Message center Manage Messages and pass messages by phone Reports Custom reports Settings modify your personal settings Current location For printing Select a location Category induction Maintenance Expl No Or Active Patients 1 T Patien Missed Test 0 1 Needs Mo next test date 2 Need Mo INF today 0 Sua FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 KA 9 9 4 List of WarnLevels Warnl evel Drugs hn EEE A e La always warm JH ______ IS 3 initial war KE Events asahan ai d a i Lata S always wa B O IS JETS IS IE E Procedures r Saswam B o O A 3 firitialy war KE JP Risks Gegen cnn ek EJ LL EJ JACET NNNM s FADEV Clinical Framew ork E Man
77. and choose from one of the lists of drugs May Flora 11 11 1944 454563 4 The Square Bolton le Sands r drugs start date End datel Dose H T AMIODARONE 30 07 2012 200 mg once daily Significant enhanced anticoagulation effect Interactions will be highlighted if used locally FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 10 4 10 5 Reminders The Reminders list view is useful for finding current or overdue Reminders on various patients The lead days are the number of days before the due date for which you wish to have the Reminder flagged on the Patient screen and the list view Filter With Current amp Overdue 11 records found NHS No Reminder TestPatient Amy check weight and height 20 11 2008 7 Brown Joe Phone d 2 Add a Reminder from the main patient screen Eet E E A EE GE RE click an the add new button to add a L VOLI LEE CES P A A LY ae a E4 reminder C S c j EN click to edit or complete wem DueDate Reminder Current amp Overdue e Sch 12 02 2010 Platelets clump Hosp Scott Ann Marie Plt clump use citrate blue bottle Click on the Reminder and mark it complete List view Patient Reminder x Reminder Ian 01 01 1955 EE DESEE PE 12 02 2010 Flatelets clump e Plt clump use citrate blue bottle ES Sco Activating and deactivating patient
78. anization and specific locations within your organisation When each user logs in any messages that are triggered in response to things they do doses they accept non attenders they reschedule are handled by their organisation s Print Station These messages are printed faxed or emailed by a separate application called DAWNMailer which connects to a specific Print Station and sends out all the pending messages to the right location Drivers for all printers at each location should be installed on the server Should you have identical printers at different locations the drivers would need renaming to reflect this Steps needed to be set up for Automatic Messaging 1 Setting up a Print Station 2 Setting Up DAWNMailer to process Messages for a Print Station 3 Setting up a new Paper Type 4 Mapping Printers with PrinterPaperType 5 Setting Up a New Printing Location 6 Selecting Paper Type in Message Template 7 Selecting Paper Type in Message Event 9 27 1 Setting up a Print Station e Press F5 to display the system menu and choose Management Printing Print Station If you are on DAWN version 7 0 choose Normal Tables Print Station to display the Print Station screen e Choose the orange New button to add a new Print Station e Enter a name eg General Hospital FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 197 PrintStation T L Name peneral Hos
79. aptability built into the software empowers the customers with minimum IT professional help to quickly get the information they require from their system without long delays 4S DAWN Clinical Software Telephone 44 0 15395 63091 Facsimile 44 0 15395 62475 4 The Square Milnthorpe Cumbria LA7 7QJ UK E mail sales 4s DAWN com Website http www 4s DAWN com FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 2 How To Use the Manual DAWN CLINICAL SOFTWARE HOW TO USE THE MANUAL If a text bubble asks you to Click Here and a red circle is present on the bubble you will be able to click on the link to take you to the next screen For example clicking on the link on the image below will take you to another screen below Stevenson Lisa 01 01 1922 5465 7565 Risk class High Pref clinic Anticoagulation Clinic 12345 ze Phone 610 374 3522 home wi Age al get WARFARIN 10 hic WEEKLY DOSE 02 05 2009 Treatment stopped m 4 1 b ofi stopped i FESSA DELI i f 1 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 AAA AAA Hyperlinks move to the Next Screen Patient Diagnoses 3 2 1 Lisa 01 01 1922 ua DiagnosisNotes Recorded by pport 4572 iN E B MUN EN E UM fa ANGINA 20 04 2009 Ee lin Hasnital Su
80. ar Non VKA 21 12 2012 Rivaroxaban 20 mg Once Daily SEET E Treatment Plan 1 ofi New back to Initiation Questionnaire page back to FAQs page back to Risk Settings page 6 1 2 9 Rivaroxaban Dose The dose recorded on the Initiation Questionnaire may be chosen from any regime for this anticoagulant on DAWN Dosing regime Advice Hivaroxaban 20 mg Once Daily Recommended dose maximum recommended Hivaroxaban 15 mg Once Daily Recommended for moderate to severe renal impairment 15 49mL min creatinine clearance Suggested dose 20mg once daily with the evening meal Please use your clinical judgement before deciding on the most appropriate dose Click for more details on Xarelto Rivaroxaban Dose Rivaroxaban 15 mg Once Daily None selected Hivaroxaban 20 mg Once Dail Rivaroxaban 15 mg Once Daily This screen shows advice for permitted regimes set for the chosen Therapeutic Indication at the top of this questionnaire To update or change the displayed options request that your system administrator edits the settings for Anticoagulation Tables FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 back to Initiation Questionnaire page 6 1 2 10 CHADS and HASBLED scores 6 2 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 CHADS2 and HASBLED scores may be optionally recorded form the dr
81. arance e Moderate to severe renal impairment is defined as measured creatinine clearance 15 50 L min or estimated glomerular filtration rate 15 60 mL min or Cockcroft Gault estimation of CrCl 15 50 min Note 15 50 is taken to mean greater than equal to 15 and less than 50 back to Complete a Follow up page 6 3 2 5 Contraindicated drugs Some concomitant drugs may be known to be contraindicated for the chosen anticoagulant as published in the prescribing guidelines Please tick any drugs if your patient is currently prescribed this drug OTHER ANTICOAGULANT HEPARIN DABIGATRAM DRONEDARONE TRACONAZOLE KETOCONAZOLE POSACONAZOLE RITONAVIR SINTHROME WARFARIN The list of drugs displayed are defined in the Look Up Tables on your DAWN database and additional drugs may be added to this list as required Please contact your system administrator to add new drug settings to the Interacting Drugs table back to Complete a Follow up page 6 3 2 6 Interacting drugs Some interacting drugs may be known to be increase the haemorrhagic risk if used along with the chosen anticoagulant See relevant published prescribing guidelines Please tick any drugs if your patient is currently prescribed this drug F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 3 2 7 6 3 2 8 ASPIRIN CLARITHROMYCIN OTHER NSAIDs TELITHROMICIN VORICON
82. arin 1 and Seng in Tal Dabigatran 110 mg Twice E Warfarin 1 and Smg in Tal ged Dabigatran 110 mg Twice E e Climie summary Regime Rivaroxaban 15 mg Once in 150 mg Twice 14 06 2013 6 3 1 Schedule a Follow up Non VKA Black Sarah 06 03 1932 HY8997430 14 Foundry Lane BlackTown Risk dass igh Rivaroxaban Contacts a Pref dinit HOAC Clinic Big Hospital B Riarexaban therapy is managed using Questionnaires Fhone 015395 63091 home Asa 81 To schedule quesbonnaire EE ee Arial librllation nonvalvular En Start date 1405 20131 Indedinite 2 Set the due date as appropriate Anticoagulant cL 20 mg Once Daily 3 Press OK 4 1 b ofl active Target Range Mona i Press the im Click on the yellow star to add a questionnaire forthis patient Quectionnairerype Entry date Summary Personal Trestment plans Questionnaires Test Results bution on the Questionnaires tab to create a new ques Rraroxaban Candidate 30 05 2013 11 15 GFR 58 mL min Dase 20 mg once daily On adding an Follow up Questionnaire change the Due Date to the date you will complete the details Rivaroxaban Follow Up Patient Name Sarah Black Date of completion 06 06 2013 11 00 Click OK at the bottom of the Questionnaire screen to save this Initiation with the scheduled date I OR Cancel You will find the questionnaire on the questionnaires
83. ass Severity Type i RiskClass Reports Custom reports Application rea amp Diagnosisaroup e DiagnosisStage Settings Discipline Modify your personal settii Meeting Type e Drugbosellnits amp OrugQurationUnits Current location For printing Select e OrugMedium d Category Induction DrugvolumeLlnits No of Active Patients 1 Frequency Missed Test o amp warnLevel Mo next test date e Visit Type EH i Ma INR today o i InterventionTimeslak Ma dose today o e LMWHdrug Poos acbrand LA CE ET CessationReason Pending Messages Waiting FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 13 1 List of Cessation Reasons CessationReason i3 Advised Course Completed Advised Course Completed EEC NS P Y MajorBleed fp L Rheumatology Y fallergicreaction JB dS gt Y fooorresponse Bd FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 13 2 Choosing Cessation Reason Application Area CessationBP eason New record Please select a 4pplication4rea For the table CessationReason Anticoagulation Clinical Haematology Rheumatology FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 13 3 Cessation Reason Form Cessa
84. ateafbirth 2 Add the patient details 1 Patient Details EE identification numbers name and address etc or update a previous lastname P E record as required Hoo Sex None selected Assessment as a Candidate for Rivaroxaban Initiation Patient Nama Trevor Toast Date of completion 35 2013 3 Complete an Initiation C mede Questionnaire Unit No 545 5455FF Status Complete Answers 4 Stop any existing treatment plan Warfarin Mixed Tablets Weekly for other anticoagulant or dose Treatment Plan DAA mee c FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 5 Activate a treatment plan for the Risk class chosen anticoagulant and dose E SUE SC Pref clinic NOAC Clinic Big Hospital Phone 015395 63091 home d Age 62 Lipi trial fibrillation nonvalvular Non VKA 13 05 20137 Indefinite Rivaroxaban 20 mg Once Daily Treatment SEI 4 1 b ofi active Risks poor complaince 6 Schedule the next follow up as EEEN a Follow Up Questionnaire TEENETE TENT OEE Za Rivaroxaban Follow Up 30 05 2013 ta Rivaroxaban Candidate 01 03 2013 10 00 GFR 68 mL min Dose 20 mg once daily 7 See the FAQs page for some common queries on the Non VKA Workflow Don t forget to chase patients due for follow up at regular intervals you ll find them listed on the list vew for Non VKA v HINT At some
85. ating a new clinic FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 A 0 y y AAAAA License_MaxActivePatientCount Fou are current fogged an ap Sunport 35 t wrer proble Too Grade Frontpage E Normal Tables M CLINICA amp Healthauthority D AW N C LI VICA L Organisation RAMEVVORK d e ward amp HCProfessional Clinic PatientGraup LoginLog e Clinic diary Meeting MeetingTemplate e Test Wi O ReferenceRange TestGroup Therapy Template e Trial e DrugTemplate QuestionnaireType Anticoa Patient view Add edit or dose a patient List view Daily routines Attendance and nan attendance Diary Consult the diary Message center Manage messages and pass Messages by p amp GeneralLookupCategory ia Reports Team Custom reports SLookup tables Reports i REPE o i Settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh 9 16 1 List of Clinics Clinic Application Area Organisation Description B Anticoagulation 45 Dawn Clinical Software Anticoagulation Clinic IEN ApplicationArea Anticoagulation ka Description hinticoagulation Clinic Organisation 4s Dawn Clinical Software an the Localt ode InUse xi RECHT e 09 00 17 00 B8 hours FADEV Clinical Framew ork E Manual Non V KA DAWN Non
86. care Professional to display their full details 3 Choose the Account tab and enter the user s Active Directory Network User ID in the Network Name field HCProfessional Organisation Big Hospital ei HCProfessionalType TT m LastName FirstName Initials EN InUse B Account info b ii User awn Yes Click to reset password Hu 20020 E Failed login count total 24 Locked 1 Last login date 29 06 2009 1 Total number nf logins 193 E UserProfile Top Grade hl NetworkName Disabling Anonymous Access to the DAWN website PasswordExpirationDate Failed login count 4 Right click on My Computer and choose Manage from the pop up context menu to display the Computer Management Console 5 Expand the Services and Applications branch of the menu and click on nternet Information Services 6 Expand the Web Sites folder right click on the Web Site which hosts DAWN and choose Properties from the pop up context menu The web site properties are displayed 7 Choose the Directory Security page and click the Edit button in the Anonymous Access and FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 3 Authentication section BR Computer Management Action View Ox Es Tree Default Web Site 2 E gd Scripts 8 TISHelp E IISAdmin ce d II55amples
87. d Al All patents lll All risk dasses ie Wise Ernest 784567894 04 09 2012 All diagnoses ud Stephenson Hedley 123456 05 09 2012 Next 7 days Important notes on using filters more than one filter may be chosen in the control panel on the left at any time The following example selects patients in the Postal clinic who have Scheduled or Overdue appointments for review WARNING With Scheduled amp Overdue bi All All patients All risk classes e All diagnoses M All Postal Clinic St Elsewhere Next 7 days Each filter can then be removed by choosing the default option like All clinics again Please note A The With or Without option applies only to the uppermost filter i e Scheduled amp Overdue in the example above In this case changing the setting to Without would select all patients in the Postal clinic who do not have scheduled or overdue review appointments on DAWN It would not select patients who are not in the Postal clinic e If you use filters to work with subsets of your patients you must always check the unfiltered list to find patients who do not fit any of the criteria you select For example you may wish to divide up checking flagged results by assigning one clinic to one member of staff and another clinic to a different member of staff Each person uses the clinic filter to show patients in their clinic and works down thei
88. d to save this new record before you can add related ecords Notes Finish West step back to detailed Non VKA workflow page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 AAA 10 1 2 Wizard Screen Entering Treatment Plan Start date 4 09 2012 Transport needs Duration type Notes Duration First seen date Preferred clinic Preferred time Next test date Laboratory f Set the status of the TreatmentPlan to Active Requires a Set the status of the TreatmentPlan to Admitted see suggested steps to monitoring non VKA patients on DAWN for some hints and tips FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 10 1 3 Wizard Screen Next of Kin Details New Patient Wizard f Y F Step 3 Next Of Kin Details 4 Name Address Home phone Mobile phone Work phone Fax number Email address Messaging method None selected Mex step lt Previous step Finish Cancel 10 1 4 Wizard Screen Clinical Details New Patient Wizard Step 4 Ginical Details Additional diagnoses Allergies There are no items to displa here are no tel Blood group None selected High risk Weight kg Measuredat Height m Measuredat est step z FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban
89. dance Diary Consult the diary ll sa Message center Manage messages and pass messages by phone Reports E Custom report 4 Settings Modify your personal setting Current location for printing Select a location Category induction Maintenance Fx Mo ot amp ctrye Patients 1 5 Pahents on Treatment Now Missed Test O Needs rescheduling No next test date d Needs scheduling No INF today i O Awaiting result yet to athens Ho dose today O 0 Needs Dose Instruction This secti Explanation Pending Messages Wailing to be se Availting Acknowledgement Awaiting Thi Undelverable Messages Failed t yc stopped AC Messages On Hold 0 Messages On Hold Test Result Errors D 8 6 List Views What are They List Views are lists of patient records selected and ordered on predefined criteria Use List Views to quickly access records for patients due for review today patients with missed reviews reminders outstanding Up to 10 List Views can be configured in your DAWN system FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 The user can apply filters such as date range or patient status to refine the list of records viewed Bulk messages can be sent for patients identified on a List View If you edit amend list vews within the system remember to check all changes thoroughly This can be done using a dummy patient within th
90. dures should incorporate not only necessary operational steps FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 but safety steps The computer system along with these written procedures should form part of a quality management system Subject this system to external auditing by a suitable quality standards authority Appoint a competent healthcare professional to carry out the patient monitoring Train staff in the use of the computer system Check that all non attendees are followed up and every patient has a next review date DAWN Rivaroxaban module provides the use of List Views to aid in identifying the following e non attendees e patients with no next review date GO BACK TO MAIN PAGE 3 2 Safety Check List for Adding Editing Deleting Letters Messages e Ensure all new altered and imported letters message templates have been checked for correctness and have been thoroughly tested before using them in a live situation e Check the correctness of all letters messages sent out from the system This should be carried out for all available methods of communication including printed output emails and faxes e To prevent the wrong information being communicated to a patient or healthcare professional where possible include the patient identifiers in any printed output emails and faxes e g dose instructions e To prevent the wrong dose instruction being commun
91. dvice Hivaroxaban 15 mg Mormal Dose Day 1 21 Twice Daily Hivaroxaban 20 mg Normal Dose Day 22 onwards normal renal function to severe renal impairment CrCl gt 15mL min Once Daily Hivaroxaban 15 mg A reduction of the dose from 20mg once daily to 15 mg once daily should be considered if the patient s Once Daily assessed risk for bleeding outweighs the risk for recurrent DVT and PE The user chooses the dose from a drop down menu Rivaroxaban Dose None selected id None selected Hivaroxaban 15 mg Twice Daily Hivaroxaban 20 mg Once Daily Hivaroxaban 15 mg Once Daily The dose is assigned for each patient using the Initiation Questionnaire and this links to the patient s treatment plan which must have the dose and Primary Diagnosis set as indicated in the questionnaire If there is a discrepancy in the information entered for your patient a warning is displayed on screen This dose is not appropriate for this therapeutic indication The settings for dose options may be updated as new medical evidence emerges using the Look Up Tables in DAWN FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 5 4 5 back to Help page Overview of Validation Checks Activation of a new treatment plan for non VKA on DAWN triggers some background checks as follows If the user selects activate and all checks pass the treatment plan is activated without error If there is
92. e Contraindication eL NB deletion of an entry for Specific Risks may cause loss of information in any patient questionnaire not completed or unlocked for editing FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 247 Technical note the table name for Specific Risks is AnticoagulantRisk 16 7 Permitted Regimes COPY Checks are made on first activation of a treatment plan and on saving an Initiation Questionnaire on the settings stating which regimes e dose of Dabigatran for example are appropriate for which primary diagnosis or therapeutic indication Additional regimes can be added to this table as appropriate Permitted Regimes Therapeutic Indication ESS Dabigatran AFNR Atrial fibrillation nonvalvular le dia 150 mg twice daily T dose ES Dabigatran AFMR Atrial fibrillation nonvalvular Dabigatran 110 mg twice daily Patients aged EE Dabigatran AFNR Atrial fibrillation nonvalvular Dabigatran once daily The Clinical Advice is displayed on the Initiation Questionnaire screen as below and the Order number is relevant for display on the questionnaire screen Valid regimes for this ir Dosi a Advi Dabigatran 150 mg twice daily Dabigatran 110 mg twice daily Patients 80 or over or at risk of bleeding Dabigatran 220mg once daily NB deletion of an entry for Permitted Regimes may result in multiple patients not getti
93. e new password field This gives the criteria that the password must meet F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 The length of the password must be 6 characters at minimum The password must contain at least 3 alpha 4 2 characteris The password must contain at least 1 numeric 0 4 characteris The password must contain at least 1 Special one of ee DR S BAD HHS All character s Although these settings can be altered within the system the default requirements are as follows The length of the password must be at least 6 characters long The password must contain at least 3 alpha characters eg A B C a b c etc The password must contain at least 1 numeric character eg 1 2 3 etc The password must contain at least 1 special character eg 96 etc For example a password such as Tracy1 would meet these criteria Enter your new chosen password into the New Password and Confirm boxes before clicking on the Login button Username i If you want to change your password please also fill the folowing feo felds If your password change has been successful the system should log you into DAWN If you are unsuccessful a message should appear telling you why ie user name incorrect password incorrect You are allowed up to three attempts at logging into DAWN before a screen appears saying Login Denied Please contac
94. e system Click HERE to learn how to use list views 8 7 Personal Settings DAWN Personal settings are user specific and can be used to determine which tabs and screens the user will and will not Mew within the system aut wre prone Top Grace LAL i C JIC Tue 23 06 2009 DAWN J 9 Version 7 9 1245 j FA y Am Anticoagulation Patient view I3 Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary Message center Reports Settings Modify your personal settings Current location for printing Select a location No ot Active Patients B Patients on Treatment Now Missed Test 0 Needs rescheduling Mo next test date 2 Needs scheduling FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 7 1 8 8 Personal Settings Form Personal settings HiddenPatientTabSheets Letters Drugs Events Procedures Reviews Reminders Groups Documents Owners Audit Graph History NextofKin Clinical TreatmentPlans I Questionnaires PatientResults InboundMessages InitialPatientTabSheet None selected v Initial isitHistoryDisplay Show both the Interventions and the PatientResults v SuppresSentMessagesNotifications O SuppresTreatment Warnings LocalSettings_PatientHeight None selected
95. e warnings on discrepancies in the recorded details The system also performs some validation checks and highlights any discrepancies when the user activates a new non VKA treatment plan click here to go back to Overview page back to FAQs page 5 4 1 Contraindications Contraindications are highlighted in RED on the Initiation Questionnaire and shown on the Questionnaires tab Summary comment Pop ups will also highlight contraindications on attempting to proceed with a plan for Rivaroxaban TT Questionnaire screen shows a red X fv ITRACON PO o0 859 22 RRS Ser RR Summary shows contraindicated aa Pe a I Y Rivaroxaban Candidate 30 05 2013 Contraindicated Please check the Initiation Questionnaire Dabigatran may be E contraindicated for this patient Pop up warning example FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 The settings for contraindications may be updated as new medical evidence emerges using the Look Up Tables in DAWN back to Help page 5 4 2 Renal function Renal impairment may affect the appropriate anticoagulant or dose and renal function may be recorded as measured creatinine clearance estimated GFR or the Cockcroft Gault estimation of creatinine clearance DAWN provides a calculator for the Cockcroft Gault estimation from serum creatinine and body weight Measured Creatinine Clearance mL min Age at due date 52
96. eason back to Complete a Follow up page 6 3 2 3 Adverse events reported Please tick any of the adverse events which apply to your patient These events are identified in prescribing guidelines as significant events for consideration in dosing decisions for Rivaroxaban Has the patient reported any adverse event potentially due to current anticoagulant ES Anaemia Bruising Change in colour of stools Epistaxis Haematoma Vomiting blood The list of adverse events may be edited added to by your system administrator using the General Look FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Up Category Table called Adverse Bleed Events NB any events identified on the Follow up Questionnaire will NOT automatically display on the Events tab of your patient screen Please click on Events tab to fully record events on the patient screen back to Complete a Follow up page 6 3 2 4 Renal function Estimates of renal function may be recorded in several ways on the Follow Up Questionnaire and these will be used to modify the suggested dose where renal function is severely impaired or not recorded measured creatinine clearance laboratory estimation Estimated Glomerular Filtration Rate eGFR serum creatinine Cockcroft Gault estimation of creatinine clearance other measures may be recorded in the notes box DAWN provides a calculator for estimat
97. easons Tor compliance proble MS EE 77 Adversa Venson A 71 Renal TELM A EI ENTM MER ele ele Or 78 EEN 79 AE RETO RTS EO SA A E crate tated A 79 Other anticoagulant or platelet inhibitor non a 80 Qer GC OMT EH ele ION rl di dean te 80 A A Ee 81 CHADS and HASBLED SCOreS unitat cabida 82 4 FAQ non VKA records on DON ugeet sia 83 Part VII Changing Anticoagulant 86 1 Changing between different VKAS see REENEN ENER 86 2 Changing type Of NON VKA crain a rada 86 3 Changing between VKA and Nnon VKA ooococoncncocococcocococoncocoroconnacararonnacararnnnarararnrnanararnrnananass 87 4 Bridging VKA Anticoagulation with LMWH eeeeeeeeee eee 87 Part VIII Using the system 90 F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LE kg Pb c Mech oO 9 10 Part IX 1 10 11 LOGGING INTO DAWN n X X 90 Logging In Active Directory SUPPOSt ccccceeeceeeeeeeeeeeeeeeeeeeeeeoeseseeseseeenseeonsesonsnseesneeeones 92 Workflows in DAWN an OVervVie W oooccccccoccnconcnccnconcncancnenncncnnrnnnnennrncnnrnnanrnnanennrnnanennanennannas 94 How To Navigate Around DAW IN eege 95 L gin CONTIPM atlOll SCV EE 98 DAWN elei SE 99 DAWN EON PaO dolar cad 100 List Views What are They 7 cenana corone a dar 100 Personal SENING S er a 101 Personal Settings FOLI E 102 Getting Started We d e e UE 102 Prinung rom
98. ed an ar Support 35 with Geer profe Too Grade d un d C MJ I C A i FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 nticoa Patient view Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary Message center Manage messages and pass messages by p Reports Custom reports Settines 14 06 2013 117 9 4 1 List of Drugs Search for Description Relevant interaction Relevant interaction Relevant for Eg a pEoxvcvcLINE JiNone selected Bl O anticoagulation clinical Haematology Ce E Rheumatology clinical Haematology E Rheumatology E Anticoagulation Clinical Haematology a Rheumatology E Anticoagulation clinical Haematology E Rheumatology imone selected E Anticoagulation clinical Haematology E Rheumatology ES aorar one selected T anticoagulation P clinical Haematology E Rheumatology EEG ALKA SELTZER JiNone selected H E anticoagulation 09 S clinical Haematology E Rheumatology x E Anticoagulation Clinical Haematology E Rheumatology Els AMILORIDE L ES r Anbhirnani latinn x e Down eut Hs Ci Lose FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 4 2 Adding a New Drug
99. ed for correctness e Ensure all patient reminders that are entered into the system have been checked for correctness e Ensure the patient s risk class if applicable has been correctly determined and selected e Ensure the patient has not been incorrectly marked as deceased or inactive GO BACK TO MAIN PAGE 3 15 Safety Check List for Adding Editing Patient Treatment Plan Details e Ensure all treatment plan data including all data entered via any of the tabs on the treatment plan screen has been entered and checked for correctness Attention should be paid to ensure o the correct anticoagulant and dose has been chosen for the patient o the correct primary diagnosis has been entered for the patient FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 o the correct start date has been entered o if short term the correct treatment duration in weeks and days has been entered o the correct phase of therapy was activated o the correct next test date and preferred clinic have been entered e Ensure the treatment plan has the correct status and has not been suspended or stopped in error GO BACK TO MAIN PAGE 3 16 Safety Check List for Adding Previous Treatment History e You MUST check that the historic results and notes have been entered correctly e Correct next test date GO BACK TO MAIN PAGE 3 17 Safety Check List for Recording Medications and Their Doses
100. ed from DAWN by saving as a text file or e mailing to yourself or a colleague Further data analysis may then be possible using Microsoft Excel or another programme back to Workflows in DAWN page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 15 Settings for Novel Oral Anticoagulants Your System Manager can access settings for Rivaroxaban and other anticoagulants in the System menu gt Lookup tables AS DAWN Clinica Ssftvare amp Internet Applice LicenseAgreement O Frontpage Normal Tables Lookup tables Anticoagulation Tables TargetRange INR Anticoagulant i Regime Induction Algorithm ResultRange INR ACTestAlias Therapeutic Indications Qualifying Risk Factors Interacting Drugs d Specific Risks d Permitted Regimes Non VKA Dose Questionnaire Settings sl Welcome License MaxActivePatientCaul Fou are currently m The settings here are critical to how your DAWN system operates and any changes deletions additions are likely to affect the anticoagulant dosing of past present or future patients ALL changes to settings should be tested thoroughly on a test database before applying changes in your production database ALL outputs like letters e mails from the DAWN system should be checked carefully for completeness and accuracy by a suitably qualified healthcare
101. enal function is entered measured creatinine clearance is considered in preference to estimated glomerular function rate in preference to Cockcroft Gault estimation of creatinine clearance e Moderate to severe renal impairment is defined as measured creatinine clearance 15 50 L min or estimated glomerular filtration rate 15 60 mL min or Cockcroft Gault estimation of CrCl 15 50 min The DAWN system alerts you if you add an unusually low or high serum creatinine or body weight measurement If you get a warning message please check the details you entered carefully back to Initiation Questionnaire page 6 1 2 3 Contraindicated drugs Some concomitant drugs may be known to be contraindicated for the chosen anticoagulant as published in the prescribing guidelines Please tick any drugs if your patient is currently prescribed this drug F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 1 2 4 6 1 2 5 OTHER ANTICOAGULANT HEPARIN DABIGATRAN DRONEDARONE TRACONAZOLE KETOCONAZOLE POSACONAZOLE RITONAVIR SINTHROME WARFARIN The list of drugs displayed are defined in the Look Up Tables on your DAWN database and additional drugs may be added to this list as required Please contact your system administrator to add new drug settings to the Interacting Drugs table back to Initiation Questionnaire page back to FAQs page back to Interacting Drugs
102. ersion 1 0 14 06 2013 Contents 5 riti reir Eee CC C 46 Warnings on INCONSISTENCY and completeness cece ee eee eee eee nenne eene enne nennen nn nnn nnn n nnn n nnns 46 DOSING W Uu CN 47 Overview of Validation Checks iiri ie peeitr er ied re iee EE ca heu e Fue d e Aaa rencia dia ac 48 5 Reporting on the non VKA patient database eeseeeeeeeeeee nere 49 cil A anoa espose rarer sae E aaraa a aea aa e r Eseo A OA OESE EEEE 50 Example o 51 6 Other Non VKA agents Ouestonnaires ek EN REENEN ENNEN ENEE E ENEE nnn 51 Part VI Detailed Workflow 53 1 initiation Questionnaire sises a aa e 55 Schedule an Initiation non VKA WEE 56 Complete an Initiation Questionnaire ssssssssessnsunnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn nnnm n nnmnnn rr nnmnnn nnn 57 let lee euer DEE 58 Heal Re Leite EE 58 Gontralndic atea 59 ISAC UI Rol Ver 60 Other anticoagulant or platelet lee ei Lee EE 60 Yates IOMA KA repr CPP bicis 61 Other contr andic Le E 61 PIAS glas ACIC MIS EET T D ai 62 15 169 apan DOS Cruce E SES A 63 CHADS and FIASBEED SCORES sciatic Ee 64 2 Non VKA treatment DIAM DE 64 Starting a non VKA treatment DIAN egener 65 Changing a non VKA Trealment placa 68 Stoppind a hon VKA treatment plan eege as 70 3 Follow up Questonnalte ia dio 72 Schedule a Follow up Non VKA EE 74 Completea Follow up Noh V KA ebe ees Eege aa 75 Patent oues ONS EE 76 R
103. file HCProfessionall ype L HERE Big Hospital IT Support Other OrderNr InUse PF Bum FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 23 Adding Editing Healthcare Professional Types If you need to add a type for a healthcare professional that does not exist in the standard list new types can be added here License MaxActivePatientio our Fou arg current logged an ag Sunnort 35 with user proble Tap Grade Frontpage Normal Tables TU v Lookup tables D ya Anticoagulation Tables bn n E i f MEVVO e Allergy Bloodgroup i Diagnosis Drug Druginteraction EthnicOrigin e Event HCProfessionalType amp JournalltemType LetterTemplate amp OrganisationT ype e Procedure nticoad Patient view E Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary e Risk Message center Severity Manage messages and pass messages by ph e Severity Type e RiskClass ia Reports Custom reports amp Application rea Diagnosisiaroup amp Diagnosisstage o Settings ER Ine Modify your personal settings MeetingType d DeinDosel IniFs Loo FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013
104. g E Uncontrolled severe arterial hypertension Vascular retinopathy These lists are for guidance only and are not exhaustive Please use your clinical judgement before decision making Click for more details on Xarelto FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 If other please give details A Other contraindications T Clinically significant active bleeding Creatinine clearance 15ml min H epatic impairment or liver disease expected to have any impact on survival E Hypersensitivity to tablet excipients or galactise intolerance Paediatric Patient Pregnancy and breastfeeding Prosthetic Heart Valve Haemorrhagic Risks Active ulcerative gastrointestinal disease Bronchiectasis or history of pulmonary bleeding Congenital or acquired coagulation disorder Intraspinal or intracerebral vascular abnormalities Recent brain spinal or ophthalmological surgery Recent intracranial or intracerebral haemorrhage This list is for guidance onhby and is not exhaustive Please use your clinical judgement before decision making Un irolled e arterial hypertension CR WR WW SKI Vascular retinopathy These lists are for guidance only and are not exhaustive Please use your clinical judgement before decisian making Click for more details on Xarelto Rivaroxaban Dose Rivaroxaban 20 mg Once Daily Suggested dose 20mg once daily with the evening meal
105. ges NB unlocking a prevous questionnaire to edit it may cause the details to be updated with subsequent changes to the patient details For example if the patient was previously on an interacting drug which was later removed from your DAWN database the drug would still be stored in the old completed questionnaire On unlocking the old questionnaire the record for this drug may no longer be available back to Initiation Questionnaire page Therapeutic Indication The dropdown menu for Therapeutic indication displays options for the primary diagnosis The available options are those set for any anticoagulant in the Lookup Tables as Therapeutic Indications Selection of the most relevant therapeutic indication for your patient is recommended If you are unsure you might wish to complete this later Ane ee ee Atrial fibrillation nonvalvular Atrial fibrillation nonvalvular DVT Provoked DVT Unprovoked PE Provoked PE Unprovoked Recurrent DVT Recurrent PE see Lookup Tables to adjust the options displayed in this dropdown back to Initiation Questionnaire page back to Settings for New Oral Anticoagulants page Renal function Estimates of renal function may be recorded in several ways on the Initiation Questionnaire and these will be used to modify the suggested dose where renal function is severely impaired or not recorded e measured creatinine clearance laboratory estimation Estimated Glomerular Filtration
106. gulant For example the settings for Rivaroxaban may be as shown Therapeutic Indications 2 GIOICIGICIOGIO OIOIGIGICIOIO Add to these settings as required as new medical evidence emerges so that an anticoagulant is known to be approved for use with a particular primary diagnosis NB deleting entries on this table may result in multiple patients not getting a dose or next appointment back to Settings for New Oral Anticoagulants page 15 2 Interacting drugs for non VKA It is possible to link an anticoagulant with a drug which has one of the following interactions if prescribed concomitantly e Contraindication e Haemorrhagic Risk e hromboembolic Risk These settings have a notes field and the notes plus appropriate warnings will display on appropriate patient questionnaires and may prevent activation of a treatment plan see examples for contraindicated drugs and interacting drugs FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 nteracting Drugs Anticoagulant givaroxaban Drug KETOCONAZOLE Interaction Contraindication S NB addition editing deletion of entries on this table may cause checks on important drug interactions to be missed NB deletion of an entry for Interacting Drugs may cause loss of information in any patient questionnaire not completed or unlocked for editing back to Settings for New Oral Anticoagulants page
107. haemorrhage Uncontrolled severe arterial hypertension LL I M I MI INI INI Vascular retinopathy The list of haemorrhagic risks may be edited added to by your system administrator using the Look Up Tables called Risks and Specific Risks NB any risks identified on the Follow up Questionnaire will NOT automatically display at the top left of your patient screen see adding Risks for a new patient or click on Risks button to add risks on the patient screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Risk class Tests ordered el l Pref clinic NOAC Clinic Big Hospital bi Phone 015395 63091 home Age 72 i atrial fibrillation nonvalvular Non VKA 21 12 2012 Rivaroxaban 20 mg Once Daily d 1 b ofi New back to Complete a Follow up page 6 3 2 10 CHADS and HASBLED scores CHADS2 and HASBLED scores may be optionally recorded form the dropdown menus on your questionnaire CHADS score None selected C Congestive heart failure 1 H Hypertension or treated hypertension 1 A Ageolder than 75 years 1 D Diabetes mellitus 1 5 Previousstroke or transient ischaemic attack 2 HASBLED score O Risk was 0 9 in one study 1 Risk was 3 4 in one study 2 Risk was 4 1 in one study 3 Risk was 5 8 in one study 4 Risk was 8 9 in one study 5 Risk was 9 1 in one study 6 Risk not known too litt
108. he appropriate questionnaire has been completed BEFORE the treatment plan is activated For example you may select a treatment plan for Hivaroxaban 20mg once daily but forget to go through the list of possible contraindications interactions risks DAWN will prevent activation of the treatment plan and scheduling any follow up until the questionnaire is completed The requirement for a questionnaire is set in the Look Up Table called Questionnaire settings and may be updated by your system administrator to add any required questionnaires for particular drugs e the completed questionnaire has the same details as the treatment plan For example you may select a treatment plan for Rivaroxaban 20mg once daily on the Initiation Questionnaire but choose Hivaroxaban 15mg once daily on the treatment plan FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 You have selected a regime for 15 mg once daily but the Initiation A Questionnaire records the intended dose as 20 mg once daily Please correct the regime or amend the recommendation in the initiation questionnaire and include a comment to say why you are changing it back to Help page back to Settings for Regime and Dose Settings page 5 5 Reporting on the non VKA patient database The powerful SQL reporting tools in DAWN can be configured to extract counts or lists of patients on certain anticoagulants These repo
109. i 9 27 7 Selecting Paper Type in Message Event This will supersede the settings applied for PrinterPaperType in the message template e Press F5 to display the system menu and choose Management Printing MessageManagement MessageEvent e Edit the message event you are setting the PaperType for MessageEvent E Dose Letter S Written E amp bra Letter DMA Letter E Written Pl DNA Letter O written EE Manual Dose Print Dposeleter Si By phone e Select the PrinterPaperType for the message event This will ensure that the selected printer will use the correct printer paper type when generating this message event F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 InUse PrinterPaperl ype e Choose Save 9 28 FAQ settings on DAWN How do change the GP for my patient Click on Treatment plan and Referral to select a different GP Interfacing to DAWN may be installed to make this update automatically Altincum Tim a124567 4 The Square Risk dass E Pref dinic County Clinic Royal Denby e Phone 015395 63091 home I 17 02 2010 Indefinite Rheumatology Gold monitoring 2 weekly TEST 1 bk of 1 active Date of referral Referring GP 1234 Archibold Jeremy M Consultant None selected
110. icated to a patient include the current test date alongside the dose instruction e Where printing user letters messages for a group of patients have a tally of the number of user letters you expect to produce and match that to the number of user letters actually produced to avoid missing anyone out GO BACK TO MAIN PAGE FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 3 3 Safety Check List for Adding Editing Deleting Patient Questionnaires e Ensure all new altered and imported questionnaire types have been checked for correctness and have been thoroughly tested before using them in a live situation e When completing a patient questionnaire check all the captured information is correct before confirming saving or printing it GO BACK TO MAIN PAGE 3 4 Safety Check List for Clinic Diary Settings e Clinics may be added specially for review or induction of new oral anticoagulant agents or non VKA with no timeslots or patient capacity set Ensure that clinics are not over booked e Care should be taken if sharing existing clinics between warfarin and non VKA patient appointments so that too many patients are not assigned to one day GO BACK TO MAIN PAGE 3 5 Safety Check List for Defining Procedures Letters and Events e Ensure all procedures have been defined correctly in the Procedure look up table and have been made available for use by the relevant departments
111. icoagulant You may wish to record changes in your patient s anticoagulation on DAWN when Changing between different VKA s like Warfarin and phenindione Changing type of non VKA like Rivaroxaban Changing between VKA and non VKA like Warfarin to Rivaroxaban or vice versa Bridging VKA patients with LMWH back to Detailed Workflow page 7 1 Changing between different VKA s In DAWN stop the treatment plan and start a new treatment plan for a change in the patient s anticoagulant Treatment plans for Stephenson Hedley 01 07 1932 EE EES B gt Anticoagulation ATRIAL FIBRILLATION 11 04 2008 10 03 2008 stopped Disease area 5coaaulat ACTherapy C Induction PrimaryDiagnosis ATRIAL FIBRILLATION 11 04 v e Maintenance Start date 10 03 2008 TE First seen date C Manual Bridgng Duration type Long Term b wm EEN 2 0 3 0 2 5 Target mun i Warfarin 2 mg Strength Preferred clinic m None selected Preferred time Sun Mon Tue Wed Thu Fri CezcnHnnBenzoa 1 161 1551 ml Elevated str p Pils 2 5 mg Status stopped ua m MaxPercentDoseChange Note DAWN will prevent a change of anticoagulant within an active treatment plan back to Changing Anticoagulant page 7 2 Changing type of non VKA lt is strongly recommended that you stop the treatment plan and start a new treatment plan for any significant change in the patient s anticoagulation FADEV Clinical Framew ork E Manual Non V KA DAWN Non VK
112. ig Hospital Moorside Clinic Pr 17 00 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 16 6 Clinic Adjustment Form EE ClinicSlotAdjustedCapacity Moorside Clinic Big Hospital New rec E31 days Show all Description Public Holiday StartDate 31708 2009 EndDate StartTime EndTime Dy 7 EN Give relative percentage like Cap adj Res Cap adj Sun Mon Tue Wed Thu Fri Sal 1H FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 16 7 Saved Clinic Adjustment Form Clinic ApplicationArea Organisation Description Anticoagulation 45 Dawn Clinical Software Anticoagulation Clinic x gt Anticoagulation Big Hospital Moorside Clinic IEN ApplicationArea EI ze SEENEN Organisation Click here ta create the d LocalCode InUse ete sara ndare Teen aa en Pir GEESS 3182008 VITSE Tm D E D FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 16 8 Creating the Diary Clinic Anticoagulation 45 Dawn Clinical Software Anticoagulation Clinic x Be Anticoagulation Big Hospital Moorside Clinic x ApplicationArea Anticoagulation si Description Organisation Big Hospit
113. ill take you to the following New Patient Wizard screen New Patient Wizard Target range Regime Induction algorithm hone selected Start date T Duration type Duration First seen date Preferred clinic None selected A eg A a Next test date bo MaxInterva Laboratory None selected e Set the status of the TreatmentPlan to Active Requires a Diagnoss 2 Activate a treatment plan FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Watters Wilma 04 09 1912 33243434 4 The Square Dosing Pref dinic Mone selected To schedule a questionnaire 1 Pressthe button on the Questionnaires 3 Set the due date as appropriate R EO en z Personal Treatment plans Questionnaires St Elsewhere Support Dawn Referring GP updated to St Elsewhere Support Dawn 3 Schedule a Follow up questionnaire The essential choices on a DAWN treatment plan are e Primary diagnosis must be listed as a therapeutic indication for the non VKA anticoagulant agent contact your system administrator if you have problems activating your treatment plan FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 2 2 Primary diagnosis Mone selected x VALVE REP TISSUE DOUBLE VALVULAR HEART DISEA
114. ing renal function from serum creatinine and body weight Enter these 2 values and click on the Calculate Cockcroft Gault CrCL Measured Creatinine Clearance mL min Cockcroft Gault estimate of CrCl 1 23 x 140 age years x weight kg x 0 85 if female Cockcroft D Gault MD Nephron serum creatinine umol L 16 31 41 1976 serum Creatinine 138 umol L High Body Weight 59 kg Gender Female Age at due date 70 2f mL min X Contraindicated severe renal impairment Please be aware of the limitations of estimates of renal function in relation to muscle mass race and diet FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Note if you have a laboratory estimation which is less than a numeric value like 30 please enter the number like 30 in the Measured Creatinine Clearance or Serum Creatinine boxes Similarly for results which are reported as greater than a value like 220 please enter the numeric value like 220 The limits used for renal impairment are set as follows in DAWN e Severe renal failure is defined as measured creatinine clearance or estimated glomerular filtration rate or Cockcroft Gault estimation of CrCl less than 15mL min e f more than one measure of renal function is entered measured creatinine clearance is considered in preference to estimated glomerular function rate in preference to Cockcroft Gault estimation of creatinine cle
115. ious Treatment History 5 Safety Check List for Recording Medications and Their Doses 6 Safety Check List for Warnings And Contraindications Safety Areas Identified for all Application Areas 1 Safety Check List for Adding Editing Deleting Letters Messages 2 Safety Check List for Adding Editing Deleting Patient Questionnaires 3 Safety Check List for Clinic Settings 4 Safety Check List for Defining Procedures Letters and Events 5 oafety Check List for Defining Look Up Information 6 Safety Check List for List View Settings 7 Safety Check List for Reports 8 Safety Check List for Questionnaire Definitions 9 Safety Check List for Data and Operational Integrity 3 4 What Safety Issues Are there The DAWN Rivaroxaban module provides the functionality to manage your non VKA patients The application allows for test results and specific details to be entered and examined to highlight any known contraindication or risk The application should be seen as an aid to the Healthcare Professional It is a condition of use that all instructions or information issued by the application are checked by a competent healthcare professional before instructing the patient Inadequate reviewing of patient results and the next review date could cause severe injury or death Check that all medication dosages are correct before instructing the patient Develop written procedures to use with this system to meet your local needs These proce
116. ith real patient data FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreerment Welcome License MaxActivePatientCeunt Fou are currently logged an ar Sunport 45 th user profite Top Grade 5 Frontpage Dium o P FRAMEWORK f a 5 Normal Tables Anticoagulati 5 Lookup tables Reports 5 Management 73 Clinic View settings MessageManagement MessageTemplate MessageEvent p Patient view el ies Eu Add edit or dose a patient C3Printin Re giel List view Daily routines p Attendance and non attendance Y Parameter Report Har Tro Peparing um diar Audit amp security DawnInterface M See E system essape centel Manage messages and pass messages by phone CodedComment ila Reports Custom reports Settings Modify your personal settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 12 1 List of Message Events MessageEvent EventType Template Patient message Eg 5 Dose Letter Patient_ManualMessage k Dose Letter a written Eg DND Letter Patient_ManualMlessage hal DNA Letter 2 written FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 12 2 Adding a New Message Event MessageEvent New record
117. ivaroxaban Each patient has a treatment plan when they start a particular anticoagulant treatment The treatment plan defines the key elements of the treatment such as dose duration etc JAC Anticoagula iian 27 02 2013 Indefinite 2 0 3 0 2 5 Target Anticoagulant Warfarin 1 and n Tablets Daily with Halves Referri uam Surgery Bloggs Frank da 21 12 2012 Duration Treatment stopped Stopped at 27 02 2013 16 32 Target range Non VKA Anticoagulant Rivaroxaban 20 mg Once Daily Referring GP Big Hospital Support Dawn Side effects QuestionnaireType lEntry date ET Y Rivaroxaban Follow Up 30 05 2013 CA Rivaroxaban Candidate 01 03 2013 10 00 GFR 66 mL min Dose 20 mg once daily Za Dabigatran Initiation 15 01 2013 Contraindicated See below for full questionnaire screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh For Warfarin the History tab shows details of the INR and dose history P Date MR Bose Dosing Instructions Time lBHA Inrange Commen Sab24 058 20011 331 75w Sun Mon Tue Wed Thu Fri Sat A wk al te 2 Lk 2 lH 2 201 FILLS 1 MG SIZE PER DAY Above ra nge 2178 Sab0305 2011 22175w Sun Hon Tue Wed Thu Fri Sat 3 wk 2 14 2 ie 2 mm 2 TELS 1 MG SIZE PER DAY Sal 2008 2011 21175w Sun Mon Tus Wed Thu Fri Sat Z wk 2 19 2 14 2 14 2 PILLS HG SIZE PER DAY Sal 1
118. k E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Disease area Anticoagulation PrimaryDiagnosis ORTHO KNEE Total knee repli e Start date 06 09 2012 EE First seen date EH Duration type Short Term M Duration Ceci Joa 12 wks Due to stop amme Preferred clinic Mone selected Preferred time From until CessationReason Patient decision Status active Admit Ka O MEN Ka increasing GI upset switching to warfarin for remaining 4 a weeks GP informed AC Anticoagulation 25 10 2012 2 0 3 0 2 5 Target caia img Strength in Tablets Daily Avg Start date 06 09 2012 7 Duration Treatment stopped Stopped at 25 10 2012 Target range Non VKA Anticoagulant Dabigatran 220 mg once daily Referring GP Consultant Notes easing GI upset switching to warfarin for remaining 4 weeks GP informed Cessation Reason Patient decision back to Detailed Workflow page 6 3 Follow up Questionnaire To review the dose for a patient on Rivaroxaban or other non VKA agent locate the patient record using either the search facility or the list vew Patient view B Add edit or dase a patient FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 List view Daily routines Attendance and non attendamce None Scheduled New treatment plan Hame Hospital
119. k Patient Adding a Clinical Framework Patient 210 Coded Comments 146 complete 5 7 75 compliance 77 consultant 205 consultant s patients 205 Contraindications 45 Creating the Diary 160 Customer Software Use Obligations 29 D Data Exchange 194 decrease dose 68 default clinic 205 delete a questionnaire 57 75 diagnosis 32 different VKA s 86 DNA 2931 dose 218 dosing warnings 47 drug 218 x Ba Editing Existing User Profiles 177 Export 195 a n find 205 Follow up 41 follow up questionnaire 72 Front page 100 haemorrhagic risks 81 HASBLED 64 82 HCProfessional FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Index 251 HCProfessional Adding 183 Editing 183 Health Authority Adding 161 Editing 161 Health Authority Form 163 Healthcare Account Information 187 Healthcare Professional Form 186 Healthcare Professional Password 188 Help with recommended guidelines 45 Import 195 increase dose 68 Initiation 37 interacting drugs 79 ei s late 231 letters printing mailmerge 103 List of Blood Groups 111 List of Clinics 153 List of Diagnoses 114 List of Diagnosis Groups 126 List of Diagnosis Stages 129 List of Drugs 117 List of Events 120 List of Health Authorities 162 List of Healthcare Professional Types 182 List of Healthcare Professionals 185 List of Message Events 141 List of Message Te
120. l Y to paste in the key Test Fax H messages sent Total lU Printed O This configures this copy of Email 0 ler to process Fax E messages For this Print Station Time of last message IF vau share Dawn AC with other organisations each organisation can have its own print station and GawnMailer Error z1 45587210 The system cannot locate the object specified 5 Press the Test Mail Test Email and Test Fax buttons to print email and fax a test message to ensure DAWNMailer can print email and fax successfully FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 Press the Start button to start DAWNMailer DAWNMailer starts processing any messages for its corresponding Print Station 9 27 3 Setting up a new Paper Type e Press F5 to display the system menu and choose Management Printing PrinterPaper Type e Select New PrinterPaperType New record Name OrderNr InUlse E Printers nu Will need bo save this new record before you can add related records e Enter the Name of the Papertype and order you want it to display in the list e Choose Save 9 27 4 Mapping Printers with PrinterPaperType e Press F5 to display the system menu and choose Management Printing PrintStation Name a Remote IP addresses Identificationkey mg ReturnEmailAddress EB E Er ell EN ES General Hospital E 1641D66FB8273COD8
121. l pdf Version 1 0 14 06 2013 2 Enter any notes about the team optional 3 Press the save button to create the new team so you can add team members Team New record Organisation Name Notes InUse TeamMember 9 25 4 Adding Team Members Once you have created a new Team you can add members to it at any time using the Team Member list on the Team screen F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 HINT It is best to add more than one team member to every team so that patient records can be dealt with when a colleague is absent 1 Click the new record icon next to the Team Member list A healthcare professional selection list appears 2 Select the team member from the list and press the OK button The new team member appears in the team list Click here to learn how to use the List View Team filter to find patients for specific teams 9 25 5 List View TeamFilter with Scheduled Tests fal All patients 44 All w All clinics hal List view Filter With Scheduled Tests records Found Time Mame Test Date INR Target TIR Drugs Events Pri 09 00 yetanother test 09 07 2009 0 00 2 50 40 09 00 Pye Delia 25 06 2009 0 00 2 50 100 03 00 Fielding Mina 31 07 2009 0 00 2 50 65 09 00 Stellar Steven 03 07 2009 0 00 2 00 100
122. lar accident Deep vein thrambosis Diarrhoea and vomiting Anticoagulant Dabigatran 150 mg once daily Mi Show repart Download as XML Download as Text A pes Events all areas Event date Therapy tee A id la Evert Seer d 03 05 7012 Dabigatran 150 mg once daty Current Lancaster Eric 12 06 1934 5875547 Cerebral vascular accident Major Hospitalisation back to reporting page 5 6 Other Non VKA agents Questionnaires Please note this module can provide support separately for other agents besides Rivaroxaban through specifically designed questionnaires for each agent Please call for a quotation Also future releases for the DAWN Rivaroxaban module are planned to include a questionnaire for perioperative situations Contact 4S DAWN Clinical Software for more information at sales 4s DAWN com support 4s DAWN com 015395 63091 click here to go back to Overview page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 EE 6 Detailed Workflow The following workflow describes how to add and deal with a new patient on non VKA therapy or edit an existing warfarin patient so that are logged as being on non VKA therapy The essential steps in recording non VKA anticoagulation are as follows 1 Check if the patient details are a Selection Active patients Patients with active Treatme already on DAWN see patient CH Search for Last name search 4 D
123. ld Jeremy M Consultant gt Hosp Blue Betty bd ReferralNotes cem How do select the same Clinic every time FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf 14 06 2013 207 Choose your default clinic setting using the Settings option on the front screen E o Ll ELM eae eae 1 j ikti i en CLINICA KA S LU k a Rheumatology Patient view Cal Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Lm Consult the diary Message center gt Manage messages amd pass messages by phone SS s e 3 el Reports a Custom reports Si Modify your personal settings HiddenPatientTabSheets Click on the yellow star to add the default clinic F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 r autmcr1us culus InitialPatientTabsheet History suppressentMessagesNotifications IT 5uppresTreatmentWarnings LocalSettings PatientHeight eege LocalSettings PatientWeight FE EE EnableCustomizedWeekPatterns xi Default Clinics per ApplicationArea uM Disease area Chnic Gi Rheumatology Default Clinic Big Hospital This will save you a step every time you add a treatment plan FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 10 Adding a New Patient
124. le data 7 Risk not known too litte data 8 Risk not known too litte data 9 Risk not known too little data The dropdown options are provided from the settings in your DAWN Normal Tables General Lookup FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Category CHADS2 Score and HASBLED You may wish to request that your system manager updates the options available back to Complete a Follow up page back to Settings for General Lookup Category page 64 FAQ non VKA records on DAWN Q Problems activating a treatment plan A Check the following 1 Is the patient is marked Active on the You may need to click on Activate or Re activate Personal tab 2 ls an Initiation Questionnaire is showing You may need to complete a questionnaire which is still with a dose on the Questionnaires tab marked as Scheduled 3 Has the Initiation Questionnaire has Check that the same diagnosis and dose have been different details chosen in both the treatment plan and Initiation Questionnaire 4 Is the Initiation Questionnaire marked as Check that the therapy is suitable for the age contraindicated diagnosis other medications if it is your DAWN settings may need to be updated by your system manager contact support 4s DAWN com for assistance Q Why is my patient not on the non VKA list vew A Check the following 1 Has the patient
125. lf users need to check that the are clear so there is no scope for confusion Losing Track of a Patient It is vital that a patient does not get lost within the system e g treatment plan wrongly closed no next test appointment made no follow up on non attendances Ensuring Operational Data and System Set up Integrity Itis essential that the system and procedures are critically examined initially and routinely to ensure that the whole system integrity is maintained at all times This safety section is intended to highlight potential safety issues that must be understood and addressed before using the DAWN system It is vital for the on going safe operation of your software that users of the software are aware of the Safety Instructions as detailed in this manual Please keep this section of the manual in a safe place for ready referral by your staff The following section is split into the following areas below Safety areas identified in all application areas are divided into one group while separate anticoagulation and clinical FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 framework sections are listed below Safety Areas Identified for Clinical Framework Area 1 What Safety Issues Are there 2 Safety Check List for Adding Editing Patient s Details 3 Safety Check List for Adding Editing Patient Treatment Plan Details 4 Safety Check List for Adding Prev
126. limit If switching from VKA is the INR stil elevated Delay staring Ri E FILET and Ee deene na Reet for UW and prevention of recurent 1 m e D e A Pa en 2 E back to Initiation Questionnaire page 6 1 2 7 Other contraindications Please tick any of the other contraindications which apply to your patient These risks are identified in prescribing guidelines as contraindications for dosing with Rivaroxaban Other contraindications Clinically significant active bleeding Creatinine clearance 15ml min Hepatic impairment or liver disease expected to have any impact on survival Hypersensitivity to tablet excipients or galactise intolerance Paediatric Patient Pregnancy and breastfeeding LI S IN ML MI MUI Prosthetic Heart Valve The list of contraindications displayed on the Initiation Questionnaire may be edited added to by your system administrator using the Look Up Tables called Risks and Specific Risks NB any risks identified on the Initiation Questionnaire will NOT automatically display at the top left of your patient screen You may wish to highlight these manually on the patient screen either by adding Hisks for a new patient or clicking on the Risks button to add risks for an existing patient screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Risk class Tests ordered S Pref clinic NOAC Clinic Big Hospital hi Phone 015395 63
127. lthcare Professional Account Info eeeeeeeeeeeeeeeeeeee eene nn nnn n nnn nnn nn nnn n nnn nhan n nnn n nnn 187 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 25 26 27 28 Part X 2 3 4 5 Part XI Part XII 1 Part XIII 1 Part XIV Part XV 2 Adding Healthcare Professional Password eese eene n nennen n nnn nnn nnn nnn nnn nnn n nhan nhan nnn 188 Adding TO alinS e 188 New O A Ea aE a Aaaa a a aaa 190 Choosinga New Team Organisati ti sorires oiae nnee A i Aaaeeeaa aoaaa 190 Adding a New A 191 Adding Team Me E E 192 ListView Team EE eege Ee 193 Data Exchange to move settings eieieueueueeeeee eere eene nennen nennen nene nn 194 EXP Olt SCRE E 195 MONO FEST Sin 195 Setting up Printing User GUIA sissi aaa E E ENa 196 Setting Up a Print AA eee cocto ence aaa etait ates 196 Setting Up DawnMailer to process Messages for a Print Station eeeeeeeeeeeeeeee 198 Setting dpa new Paper nn edes a Ee Ecc aai 199 Mapping Printers with PrinterPaperType 11111Leeeeeeeeeeeeee rere nennen nennen nnne inen nnn nana annua 199 Setting Up a New Printing Location 23i eacece rne conca dei 200 Selecting Paper Type in Message Template eeeeeeeeee eese eee ne nennen nennen nnn n n
128. may be scheduled for patients starting on Rivaroxaban and the history for questionnaires is easily viewed on the Questionnaires tab B y Treatment plans Questionnaires Test QuestionnaireType 4 Hivaroxaban Follow Up 30 05 2013 Sch Rivaroxaban Candidate 01 03 2013 10 00 GFR 66 mL min Dose 20 mg once daily Patient details will appear on your Non VKA list view when the date of the next follow up is due back to Overview page back to Settings for Regime and Dose Settings page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 5 3 1 Rivaroxaban Initiation Questionnaire Assessment as a Candidate for Rivaroxaban Initiation Patient Name Test Patient NHS Number Unit No 324325555 Questions Therapeutic Indication Oe as ees eer tan oe baer an za Faller m LES E m ka HB Remember m SC requie d FOmow up quesmon Date of completion 31 05 2013 11 00 31 05 2013 EE at 11 00 4hr format NB Please check this appointment is made in your clinic diary or hospital administration system to be completed at NOAC Clinic Status Scheduled Atrial fibrillation nonvalvular airs Ear sia mata mt mgm theo ar ds Lares Soe fraa tpm eee a za m aie no tnis Eat en 5 iT HOLAS arte ine Ri raodd bhearnan Li an is Ln rebas activated FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013
129. mplates 138 List of Organisation Types 165 List of Organisations 168 List of Patient Allergies 108 List of Patient Groups 174 List of Procedures 123 List of Wards 171 List of WarnLevels 132 list vew 32 List Views What are They 100 list 32 205 Logging In Active Directory 92 Logging into Dawn 90 Login Confirmation Screen 98 Login Screen 98 Manual Links To 14 Mapping Printers to Paper Type 199 mark as completed 5 7 75 move 205 N Navigate 95 New Ward Form 172 NOAC 94 non attendance 231 non attender 231 nonVKA 34 NON VKA 32 94 non VKA 34 0 Organisation Adding 166 Editing 166 Organisation Form 169 Organisation Ward Adding 169 Editing 169 other anticoagulants 80 other non VKA agents 51 P Patient Group Adding 172 Editing 1 2 Patient Group Form 175 Patient History Viewing 223 patient questions 76 Personal Settings Personal Settings Form 101 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 252 Overview of Non VKA Monitoring Module Personal Settings Form 102 Pradaxa 32 Printing User Guide 196 Q Questionnaires 35 R renal function 46 78 reporting 49 retire 205 rewind 5 7 75 Risk 149 Risk Class 150 Risk Settings Risk Class 148 Severity of Risk 148 Rivaroxaban 34 Rivaroxadan 32 routines 94 S Safety section 17 schedule 56 74 score 64 82 Selecting a Paper Type 203 Selecting
130. n 31 05 2013 16 00 16 00 hr format HB Please check this appointment is made in your clinic diary or hospital administration system NHS Number to be completed at NOAC Clinic hd Unit No 12045204 Status Scheduled Therapeutic Indication Atrial fibrillation nonvalvular NB Remember to schedule a follow up questionnaire for this patient 5 months after the Rivaroxaban treatment plan is activated have taken the correct dose every day C Na C yes might have taken too many capsules tablets C Mo C wes might have missed one or more doses C Ho C Yes Notes F have started a new medication recently C Me C wes Reasons for compliance problems Dementia Fear of side effects Gastrointestinal Bleed Lack of information Lives alone Multiple medications Prescriptions from several doctors LL INL INL IN IN INI FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Other Has the patient reported any adverse event We potentially due ta current anticoagulant Ges NB Please follow local protocol for adverse event reporting to the relevant committee agency company Measured Creatinine Clearance lean Age at due date 52 eGFR Gender Male Serum Creatinine umol L Body Weight 1 23 x 140 age years x weight kg x 0 85 if female 83 mL min serum creatinine pmolL Calculate Cockcroft Gault CrC C
131. n nnne nnne nnns nnns nnn 203 Selecting Paper Type in Message Event lllieeeeeeeeeeeeeeeee eene e nennen nnne nennen nnn n nnns nna an nennen nnns nnns nnn 204 FAQ setungs on DAWN D 205 Adding a New Patient 210 Choosing New Patent Folio 211 New Patient Wizard Screener 212 Wizard Screen Entering Treatment Plan a 213 Wizard Screen Next or Kitt De tails aio deine erroe E RO Io P aede ota c o ee EE 214 Wizard Screen Clinical Details ue eios eee aepc eio ta eua quao eege EES 214 Wizard Screen Contact Desk 215 NeW Patient SCRE G E N 216 POGING ne E 217 Biker l c E 218 FAC ll TE 219 Activating and deactivating patient records eeseeeeeeeeeee eere eene 219 Viewing Patient History 223 Using List Views 226 NavigatInG LIS VIEWS iiisica X 226 Handling Non Attendance for Novel Oral Anticoagulant Patients 231 NON atendance Procesos 231 Running Reports 234 Settings for Novel Oral Anticoagulants 236 Therapeuuc Indicauors eto a Eeer 237 Interacting drugs Tor NON VKA ori s Uo RAnU c a RSe n EUR RN a M M REM RIEN INESE HE 237 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Contents 9 3 Specific RISKS for NON V KA noia 238 4 Regime and Non VKA Dose eeeeeeeeeeeee eere nenne nnn nnn nnn nnn ENEE 239 5 General Lookup Category set
132. n patient outcomes and population data Able to provide support separately for other agents besides Rivaroxaban through specifically designed questionnaires for each agent The DAWN non VKA module for Rivaroxaban provides structured questionnaires based on the recommended use of the anticoagulant and these include questionnaires for Initiation of anticoagulation and for routine Follow up Completion of the questionnaires can be scheduled for future dates so that the user can keep track of patients started on Rivaroxaban or due for a change to Rivaroxaban anticoagulation This software should be seen as an aid to the Healthcare Professional It is a condition of use that all instructions or information issued by the application are checked by a competent healthcare professional before instructing the D patient Inadequate reviewing of patient instructions and the next review date could cause severe injury or death Contact AG DAWN Clinical Software for more information at sales 4s DAWN com support 4s DAWN com 5 1 Non VKA list view DAWN Rivaroxaban module presents a list of patients for review today this week this month Each patient can have Initiation or Follow up questionnaires scheduled for future dates F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Hone Scheduled ch treatment plan _ a Charlie C23123123 e Lamb Spring 3542543345 Rivarox
133. nce Paediatric Patient Pregnancy and breastfeeding LL NI NI NI MI MUI Prosthetic Heart Valve FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 The list of contraindications displayed on the Follow up Questionnaire may be edited added to by your system administrator using the Look Up Tables called Risks and Specific Risks NB any risks identified on the Initiation Questionnaire will NOT automatically display at the top left of your patient screen You may wish to highlight these manually on the patient screen either by adding Hisks for a new patient or clicking on the Risks button to add risks for an existing patient screen Risk class Tests ordered Pref clinic NOAC Clinic Big Hospital hi Phone 015395 63091 home Y Age 72 ke eee Atrial fibrillation nanvalvular Non VKA 21 12 2012 Hivaroxaban 20 mg Once Daily back to Complete a Follow up page 6 3 2 9 Haemorrhagic risks Please tick any of the risks which apply to your patient These risks are identified in prescribing guidelines as significant risks for consideration in dosing decisions for Rivaroxaban haemorrhagic Risks Active ulcerative gastrointestinal disease Bronchiectasis or history of pulmonary bleeding Congenital or acquired coagulation disorder Intraspinal or intracerebral vascular abnormalities Recent brain spinal or ophthalmological surgery Recent intracranial or intracerebral
134. ng to return to the printing location screen InUse Printers in this location RL CH Microsoft XPS Document Writer Paper 44 CH WedcliHP Business Inkjet 1200 Series Paper 44 e Select save and the printing location will now be available to all users within the selected Organisation e Users can change their printing location from a drop down list on the main DAWN screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Mon 29 06 2005 DAW N J 9 Version 7 9 1245 J Anticoagulation Patient view Cal Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary Message center Manage messages and pass messages bw phone Reports Custom reports Settings Modify your personal settings Current location For printing No of Active Patients D Patients on Treatment Mow Missed Test 1 Needs rescheduling Mo next test date 2 Needs scheduling h l Ih IL 4 r Va Aiara eee oH deck bes Harel e The selected printing location is automatically saved there is no need to reselect the printing location each time the user logs in 9 27 6 Selecting Paper Type in Message Template e Press F5 to display the system menu and choose Management Printing MessageManagement MessageTemplate e Select the PrinterPaperType for the message This will ensure that the selected printer
135. ng a dose or next appointment Technical note the table name for Permitted Regimes is AnticoagulantlndicationRegime 16 8 Non VKA Dose COPY The settings for non VKA regimes link to a numeric Total Daily Dose which is stored in this table for reference Elements of the settings for a chosen regime are compared between the regime chosen in a treatment plan and that chosen in an Initiation Questionnaire Non VKA Dose Total Daily Dose ES Dabigatran 110 mg twice daily 110 mg Twice Daily 220 Ble Dabigatran 150mg once daily 150 mg Once Daily 150 Each regime for which a dose check is required needs to have a setting in this table The requirement FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 16 9 16 10 for a dose check is set in the Questionnaire settings table The settings here are critical to how your DAWN AC system operates and any changes deletions additions are likely to affect the anticoagulant dosing of past present or future patients ALL changes to settings should be tested thoroughly on a test database before applying changes in your production database Questionnaire settings for non VKA COPY Settings in the Questionnaire settings table define which questionnaires are used with particular non VKA drugs and how they are used e A questionnaire may be required to be completed before activating a treatment plan e he d
136. no Ape 2T ppointment Time Chmeoe Summary Change Charbe 023123123 58 Lamb Spring 4542543345354 72 Overdue active treatment plan ame Hospital no Age Appolntment Tim e Cinic Summary Hope Nuala 56346346 2 05 02 2013 Patient Perfect SAEN 107 ERAS NOAC Clinic Iffla Lennie 57457964 Patient Test 32432555 Dooley Roderik 34523523 Patient Test 324325555 Patient Perfect 324234343434 107 15 0 105 2013 13 14 15 Overdue New treatment plan Hospital no ES Appointment T Balloon Horace 12045204 62 13 05 2013 MOAC Che s heduled Grumble Greta 5463756541 14 05 2013 15 10 NOAC Clinic Overdue stopped treatment plan Hospital no Agel Appointme g Change Charlie C23123123 58 30 01 20 Scheduled active treatment plan Hospital no Appointme Blue Barbara Jayne 342523555 67 15 08 201 Scheduled New treatment plan Once you locate the patient record complete a Follow up Questionnaire AND add another Follow up questionnaire scheduled for the next review date back to Complete a Follow up page back to Detailed Workflow page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 scheduled means afuture date has been setforcompletion of a questionnaire forthis patient record Regime Rivaroxaban 20 mg Once Rivaroxaban 20 mg Once Regime Rivaroxaban 20 mg Once L Dabigatran 110 mg Twice Rivaroxaban 15 mg Twice Warf
137. nstruction ere are no items to display The settings are similar to VKA doses in this table except that no Instructions are required NB deletion of an entry for Regime may result in multiple patients not getting a dose or next appointment 16 3 Qualifying Risk Factors for non VKA COPY For some anticoagulants it may be important to note which reason s or thrombotic risks have caused the patient to be prescribed this anticoagulant H no Qualifying Risk Factors are added no opportunity to record these risk factors will be provided on an Initiation Questionnaire For example for Dabigatran in AF patients the following risk factors may contribute to the decision to FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 16 4 prescribe Dabigatran Qualifying Risk Factors Therapeutic Indication Risk _ mmm _ Fe Dabigatran AFNR Atrial fibrillation nonvalvular Aged gt 65 with diabetes mellitus coronary artery d e 3 Dabigatran AFNR Atrial fibrillation nonvalvular Aged 75 or over i CH Dabiga tran AFNR Atrial fibrillation nanvalvular 4 4 4 Left ventricular ejection fraction lt 40 CH Dabigatran AFNR Atrial fibrillation nonvalvular Previous Stroke transient ischemic attack or systemic e CH Dabigatran AFMR Atrial fibrillation nonvalvular e Symptomatic heart failure gt NYHA Class 2
138. ntpage Normal Tables HealthAuthority Organisation e Ward DAWN L L Reports Custom reports Anticoagulatic HCProfessional Clinic PatientGroup Patient view Q LoginLog dam Add edit or dose a patient Clinic diary e Meeting List view Daily routines MeetingTemplate Attendance and non attendance e Test ReferenceRange to Diary TestGroup CR Consult the diary TherapyTemplate O Trial De Message center DrugTemplate Manage messages and pass messages by phone QuestionnaireType GeneralLookupCategory Team Lookup tables Reports Management O Clinic View settings MessageManagement Settings Modify your personal settings Current location For printing Select a location EN Ei Printing Greter category Induction Maintenance expla Parameter Nn nf Active Patients 1 R Patient Report 9 17 1 List of Health Authorities P ULE E MOR ALLNEP LIE Lt uir IL 3 Frontpage 3Normal Tables HealthAuthority Organisation e Ward HCProfessional Clinic PatientGroup LoginLog O Clinic diary 0 Meeting MeetingTemplate O Test ReferenceRange TestGroup TherapyTemplate e Trial DrugTemplate QuestionnaireType GeneralLookupCategory Team 3Lookup tables Reports 3Management Name Addressi Address PostCode Telephone ANN ES s le n TTT eege umbris aza Jpissssesosi JB 62475
139. o synoRd JA ione selected anticoagulation clinical Haematology BR Rheumatology 3 ANTITHROMBIN 111 DECH SSS fone selected Anticoagulation Clinical Haematology IT Rheumatology E None selected Anticoagulation D AORTIC ROOT REPLACEM C Clinical Haematology m Rheumatology TUOwn ANEW Ponts FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh 9 3 2 Adding a New Diagnosis Diagnosis New record ij Description l i CodeName InUse DiagnosisGroup Diagnosisstage DiagnosisApplication rea Diagnosis pkibiagnosis diagnoses 9 4 Adding Editing Drugs If you need to add a drug for a patient that does not exist in the standard list new drugs can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreement License MaxsctiwePatientConnt Frontpage Normal Tables Lookup tables Anticoagulation Tables e Allergy BloodGroup amp Diagnosis Drug Cruginteraction EthnicOrigin s e Event HCProFessionalTvpe amp JournalltemType LetterTemplate OrganisationT ype Procedure e Risk Severity Severity Type i RiskClass amp Application rea amp DiagnosisGroup amp Diagnosisstage Welcome Fou are curent logg
140. ockcroft D Gault MD Nephron 16 31 41 1976 Please be aware of the limitations of estimates of renal function in relation to muscle mass race and diet Click to refer to dosing guidance with renal impairment Other Blood Checks FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf 14 06 2013 Version 1 0 Contraindicated Drugs OTHER ANTICOAGULANT HEPARIN DABIGATRAN DRONEDARONE ITRACONAZOLE KETOCONAZOLE POSACONAZOLE RITONAVIR SINTHROME WARFARIN LE IN IN LN IN NL Interacting Drugs Other anticoagulant or platelet inhibitor Prasugrel E Ticagrelor Other If other please give details D Other contraindications Clinically significant active bleeding Creatinine clearance 15mlmin Tu epatic impairment or liver disease expected to have any impact on survival Hypersensitivity to tablet excipients or galactise intolerance Paediatric Patient Pregnancy and breastfeeding Prosthetic Heart Valve Haemorrhagic Risks D Active ulcerative gastrointestinal disease Bronchiectasis or history of pulmonary bleeding l Congenital or acquired coagulation disorder E intraspinal or intracerebral vascular abnormalities Recent brain spinal or ophthalmological surgery This list is for guidance onhy and is not exhaustive Please Recent intracranial or intracerebral haemorrhage use your clinical judgement before decision makin
141. ocumenting all changes to system set up to show they are properly controlled and validated e Routinely checking that the DAWN Mailer program for sending e mails networking printing or faxes is operational and working correctly e Ensure your procedures are complete i e no sections have been removed and are kept in a safe and accessible place for ready reference by your users Make frequent checks that this is the case e Preventing and not allowing adding or editing of data in the underlying database by using a third party program or tool All data access must be done through the DAWN Clinical Framework e Keeping all the application files complete and together Do not copy files from previous copies of the application into the current set of files The application files have a high inter dependency and require absolute referential integrity e Encouraging use of the practice system to rehearse any infrequently used procedures before live execution e Using the practice system to test out future upgrades before applying the upgrade to the live system e Ensuring that users do not enter real or live data into it your practice system and use it operationally e Ensuring any old out of date user manuals or ebooks are destroyed and the current versions are readily available with no sections missing in full or in part GO BACK TO MAIN PAGE 3 11 Safety Check List for Adding Editing Patient Details e When adding a new patient
142. of the DAWN system F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 176 LicenseAgreement license _ MaxActivePatientlount Frontpage 5 Normal Tables Lookup tables Reports Management E Clinic View settings MessageManagement E Printing E Reports Parameter Report Polar Reporting Ab UserProfile workflow log Logged changes Readlog DatabaseconversionLog Update database 5 DawniInterface System CodedComment FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 Welcome Fou are currently fogged an ar Support 35 with user profe Tan Grade D W N CLINICAI 7 le EN FRAMEWORK f Anticoagulat Patient view GA Add edit ar dose a patient List view Daily routines Attendance and nan attendance Diary gt Consult the diary Message center Manage messages and pass messages by phone Reports Custom reports Settings Modify your personal settings 14 06 2013 177 9 22 1 Viewing and Editing Existing User Profiles Description Ton Grade Middle Grade Lower Grade INNEN gs for i j Patients jeze profiles are Interface Description Top Grade AllowCreatePatient IEN AllowEditPatientData Edit all v AllowChangeRiskClass Xx AllowEditPatientOrganisations Xx AllowDeactivatePatient x AllowViewPatientTelAp
143. of treatment plans but only one may be currently active Any significant change in the patient s anticoagulation management should be recorded by stopping the existing treatment plan and starting a new treatment plan NB DAWN will prevent a change of anticoagulant within an active treatment plan and require any existing treatment plan to be stopped DAWN provides INR and dosing screens for VKA like warfarin and questionnaires for non VKA management Each Questionnaire can be scheduled in advance and completed to store the important information for your patient Complete all sections and mark as complete oee sections on changing treatment plan stopping a treatment plan starting a treatment plan for a new patient viewing patient history back to Detailed Workflow page Starting a non VKA treatment plan The steps to starting a treatment plan for your patient on DAWN are outlined below as are the essential information you need for the treatment plan STEPS 1 Add your patient to DAWN see how to add a patient record AND add an initiation questionnaire If your patient already has a record on DAWN ensure any other anticoagulation treatment plan is stopped and click on Treatment Plan and New to add a new treatment plan FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 If your patient has no record on DAWN the New button on the Patient Search screen w
144. og Clinic diary e Meeting MeetingTemplate Test 0 ReferenceRange e Testaroup O Therapy Template e Trial amp DrugTemplate Questionnaire ype GeneralLookupCategory Team gop Lookup tables Reports 173 Welcome Fou are curent logged an ar Sunpart 45 wh usar nahe Top Grade FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 Anticoa Patient view Add edit or dose a patient List view Daily routines Attendance and nan attendance Diary Consult the diary Message center Manage messages and pass messages by p Reports Custom reports Settings 14 06 2013 174 9 21 1 List of Patient Groups Description Organisation Inuse Eg 3 Transport patients s Dawn Clinical Software 2 x Eg y Trial group Bia Hospital 2 EN FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 175 9 21 2 New Patient Group Form Organisation Fd Big Hospital le wou can add related records ORK i sante Save 9 22 Adding a New User profile Several User Profiles can be configured in DAWN and applied to different Healthcare Professionals Some users require read only access while others will need to edit certain values in DAWN See also the Personal Settings on the Front screen of DAWN each user can further modify their own access to parts
145. opdown menus on your questionnaire CHADS score C Congestive heart failure H Hypertension or treated hypertension A Ageolder than 75 years D Diabetes mellitus S Previousstroke or transient ischaemic attack HASBLED scare None selected Mone selected Or Risk was 0 9 in one study 1 Risk was 3 4 in one study 2 Risk was 4 1 in one study 3 Risk was 5 8 in one study 4 Risk was 8 9 in one study 5 Risk was 9 1 in one study 6 Risk not known too litte data 7 Risk not known too little data 8 Risk not known too little data 9 Risk not known too little data MJ P m b Mone selected The dropdown options are provided from the settings in your DAWN Normal Tables General Lookup Category CHADS2 Score and HASBLED You may wish to request that your system manager updates the options available back to Initiation Questionnaire page Non VKA treatment plan Non vtamin K antagonist therapy is recorded on DAWN using a new treatment plan 14 06 2013 6 2 1 Risk class High Pref clinic NOAC Clinic Big Hospital Age 67 Non VKA therapies have atarget range Tee Recurrent DVT of Non VKA rather than an INR range Phone 015395 63091 home HE Non VKA 03 01 2013 Indefinite Rivaroxaban 20 mg Once Daily EE eeleren patient screen as the Anticoagulant Treatment Plan SE ce b of2 active Pts Your patient may have a series
146. ose selected on the questionnaire may need to be checked against the treatment plan settings on first activation of a treatment plan e DAWN AC may prevent a questionnaire from being completed for a patient without an appropriate active treatment plan The settings here are critical to how your DAWN AC system operates and any changes deletions additions may affect the anticoagulant dosing of patients ALL changes to settings should be tested thoroughly on a test database before applying changes in your production database ALL outputs like letters e mails from the DAWN AC system should be checked carefully for completeness and accuracy by a suitably qualified healthcare professional before the patient is instructed General Lookup Category settings for non VKA COPY The general lookup category settings are used in some questionnaires Options available for answering questions on the questionnaire may be edited added to or deleted from this table FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreement zi GeneralLookupCategory License MaxActivePatientCour Frontpage Name P Description e He Ori y Organisation CodeName e Ward InUse amp HCProfessional GeneralLookup Clinic amp PatientGroup e LoginLog Clinic diar y Meeting amp MeetingTemplate e Test O TestAlias amp ReferenceRange TestGroup TherapyTemplate
147. pFields O alloweditPatientTelApprFields 1 AllowedPatientTabSheets Conta Letters Drugs Events Procedures Reviews Reminders Groups Documents Graph History Mextofkin Clinical wers Audit 4 TreatmentPlang lick here to add a new Questionnairesl is PatientResults I s I I XI XI I I I I I XI I I 4 F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 178 9 22 2 Adding a New User Profile LiserProfile Top Grade Middle Grade Lower Grade Patients Interface Top Grade Description Patient AllowCreatePatient AllowEditPatientData Edit all AllowChangeRiskClass AllowEditPatientOrganisations AllowDeactivatePatient Ki Allow iewPatientTelAppFields DO AllowEditPatientTelAppFields O AllowedPatientTabsheets MW Contacts Sd d s v Letters v Drugs v Events v Procedures Y Reviews v Reminders Groups Documents Us v Graph i v History v MexkofKin Clinical v Owners v Audit v TreatmentPlans sl I I I I I I I I I I I xl FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 AllowAdyvancedPatientTabSheets AllowDeletePatient Treatment plan AllowCreateTreatmentPlan AllowEditTreatmentPlanTestLimits AllowActivateAndEditTreatmentPlan AllowSuspendStopTreatmen
148. pital Remote IP address es Locked BR Identificationkey 1641D66F8273C9D8 Create random key Notes GS Returntmalladdress i Supported organisations here are no items to display Printers here are no items to display e Click on Create Random key to generate a unique identification key for this print station and then Save e Press the new item button to add the organisations that will use this print station to the Supported Organisations list e Leave the Printers list blank This is automatically populated by DAWNMailer The PrintStation handles all Event Messages triggered by users belonging to any of its supported organisations However if no DAWN Mailer is running the messages remain queued inside the print station You need to set up the DAWNMailer to send out the messages FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 27 2 Setting Up DawnMailer to process Messages for a Print Station DAWNMailer is installed in the Polar Studio Webroot folder on the DAWN server It can be run on the server itself or it can be copied to another machine perhaps a dedicated PC in the anticoagulation department and run there instead If you intend to fax messages DAWNMailer must reside on a computer that has a modem attached to a phone line You must also install Microsoft Fax Microsoft Fax is part of Windows XP and can be set up by choosing the Set Up
149. pport 45 11 true We are taken to this next screen Hyperlinks help you to move through the electronic manual easily FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf 14 06 2013 Version 1 0 3 Safety Manual Introduction This document is intended to highlight potential safety issues that must be understood and addressed before using the DAWN Rivaroxaban module It is vital for the on going safe operation of your software that users of the software are aware of the Safety Instructions as detailed in this manual Please keep this manual in a safe place for ready referral by your staff What Key Safety Areas Have Been Identified The following key safety areas have been identified Correct Patient Identification It is critical that the users ensure that they have identified the correct patient before taking action such as editing information dosing reports or taking any clinical action Avoiding Transcription or Transposition Errors Careful procedures should be derived and instituted to check that any transcription error or transposition of data cannot occur The aim should be to eliminate completely any such potential for this type of error Checking Clarity of Dose Instruction to Patient Healthcare Professional Itis essential to ensure that any dose instruction messages printed emailed faxed are clear and unambiguous As well as the format of the instruction itse
150. professional before the patient is instructed For a new oral anticoagulant 4S Information Systems Ltd will supply settings for Anticoagulant Regime Non VKA Dose and Questionnaire Settings Itis unlikely that you will need to modify these settings but please contact the support team support 4s DAWN com with any questions or issues From time to time you may need to review of consider updates to the following tables for a particular anticoagulant e Therapeutic Indications e Interacting Drugs e Specific Risks e Regime and Non VKA if Rivaroxaban may be used in a new condition now if new information emerges on concomitant drugs affecting the chosen anticoagulant if new conditions are found to affect Rivaroxaban therapy to set a completely new dosage and dose settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 237 Dose e General Lookup Category to adjust the dropdown menus for CHADS or HASBLED Settings scores For help and advice on editing any settings in your DAWN system please contact support 4s DAWN com 15 1 Therapeutic indications Please Note The appropriate anticoagulant diagnosis and regime need to be added to the DAWN system if they are not already there before proceeding to the step below The primary diagnosis for your patient has to be set as a valid qualifying diagnosis or therapeutic indication for the particular anticoa
151. r list checking the results However a patient who has not yet been assigned to a particular clinic does not appear on either list As such someone should always check the list for a clinics which includes everyone to ensure there is no one left with flagged results that still need checking FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf 14 06 2013 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 13 13 1 Handling Non Attendance for Novel Oral Anticoagulant Patients If a patient fails to attend for a review of their Rivaroxaban therapy update the scheduled Follow up questionnaire with a new date for their appointment __ QuestionnaireType l Ey Rivaroxaban Candidate 11 04 2013 11 00 Overdue Print any letters faxes e mails as required from the Letters tab E AA AA A A AA E a e a a You may be unable to create some letters and messages Select a Direct Print Local printer o belect a cust 2 Description CreationDate 1 amp DNA letter for Rivaroxaban follow up 06 06 2013 12 17 If a patient persistently fails to attend or have their blood tested you may wish to contact their GP or even discharge them from your monitoring service You may wish to stop the treatment plan and mark the patient as Inactive on the Personal tab Non attendance process explains ho
152. records Your active patient license on DAWN is visible on your front screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 See chapter on Dealing with Clinical Framework Monitoring for guidance on activating treatment plan for an active patient Inactivating patient records 1 Check that any open referrals and reminders are closed 2 Stop any treatment plan for the patient 3 W U AWN a Graph ho Penn recaer pam Ad bes qnt Contact hie cs cra i beier ze Bio belie Stage MaspMe uzs122257 Workihonc Fir Zen Emailuirecs Mies rmesaer 7 i Alim Mescagirgieiiod wel Comey Telephone Sii ber Cried ces Pog lt ole i ATT GER Vase eres ders la Oase REE Muse T me C Debet fron A men CES EthricDrigin Cauca EM et Active Dead E WC Heactivating patient records On the Personal tab mark the patient as active this action is reversible Deleting patient records Reports Custom reports Settings Modify your persa Current location for printing Database name pat RHdemo Patient Licenses 500 Active patient records Rheumatology 31 Gastroenterology 2 On the Personal tab mark the patient as inactive or deceased this action is reversible in There is no requirement to delete valid patient records where the patient has moved out of the area or died Once any trea
153. rts may be used to assess recorded events in relation to the anticoagulant used Example 1 Patient count by range diagnosis and duration Example 2 Events all areas click here to go back to Overview page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 5 5 1 Example 1 Report NPSA 7 8 Patient Cnt By Range Diag and Duration e i j 11111 Diag nosis AF CARDIOVERSION zi ANEURSYM ANEURSYM WITH EMBOLIC EPISODES ANGINA ANGIOPLASTY ANTI PHOSPHOLIPID SYNDROME ANTITHROMBIN 111 DEFICIENCY E Non VKA 1 5 2 5 2 0 Target 2 0 3 0 2 5 Target 2 3 3 3 3 0 Target 3 0 4 0 3 5 Target 3 0 4 5 3 75 Target 3 5 4 5 4 0 Target TargetRange show report Download as AML Download as Text Email address JSend Atrial fibrillation nonvalvular 0 Indefinite 2 4 50 Total hip replacement surgery O Indefinite 2 4 50 back to reporting page FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 AAA 5 5 2 Example 2 Report EVENTS all areas id Event Severity Minar Moderate No Hospitalization Moderate Hospitalisation Major Hospitalization Fatal Within How Many Days Of TP Start Date vants Bleed lower GI Bleed upper Gi Bleeding any other site Bruising unexplained Carabral haamorhage Lu gt Cerebral vascu
154. s Questionnaires A QuestionnaireType Entry date Y Hivaroxaban Candidate 31 05 2013 11 00 Scheduled back to Initiation Questionnaire page 6 1 2 Complete an Initiation Questionnaire The Initiation questionnaire is structured to help you record all relevant details at the time Rivaroxaban therapy is started See details of the Initiation Questionnaire If you cannot answer some questions simply click OK or Save and come back later to complete the answers Mark as complete On marking the answers as complete you are confirming that DAWN can store this record display a Summary on the questionnaires tab and check details against the treatment plan If you ve added some details in error Cancel your changes using Cancel or the rewind button at the top C DAWN If you need to delete a questionnaire completely look for the bin symbol on the questionnaires tab and of the screen save before confirming you wish to delete this record mi Iii gi y hivaroxaban Candidate 31 05 2013 11 00 Scheduled Dabigatran Initiation 31 05 2013 06 05 Scheduled If you need to add more information or adjust the Initiation Questionnaire which is already completed 1 locate the completed questionnaire on the Questionnaires tab 2 select Unlock to edit Unlock to edit FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 6 1 2 1 6 1 2 2 3 save your chan
155. s and pass messages bw phone ia Reports Custom reports Settings Modify your personal settings Current location Far printing Select a location ze FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 7 1 List of Diagnosis Groups DiagnosisGroup al Search for Mame o Of e FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 127 9 7 2 Adding a New Diagnosis Group DiagnosisGroup New record m dd d Ohad PL es SCH T me nere a He lc Name le mandatory a nd hed ame OrderNr must be unique InUse O Diagnosis 9 8 Adding Editing Diagnosis Stages If you need to add a diagnosis stage for a diagnosis that does not exist in the standard list new diagnosis stages can be added here FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LicenseAgreenment Welcome License MaxActivePatientCount Frontpage Normal Tables Lookup tables C3 Anticoagulation Tables e Allergy BloodGroup Diagnosis amp Crug amp Druginteraction e EthnicOrigin e Event O HCProfessionalType amp JournalltemType amp LetterTemplate Fou are currently logged an ag Sunport 35 with user prae Tap Grade Anticoaqulati Patient view ei Add edit or dose a patient
156. s name and number on each label and check the current label against previous ones in the book to ensure they match Check dosing information is not copied by hand to the wrong book or patient report Check that all patients including non attendees due on a particular day have been dealt with completely Check that the wrong information is not communicated to a patient by letter telephone or any other communication method Routinely ensure that all active patients have a future appointment GO BACK TO MAIN PAGE FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 OS 3 13 Safety Check List for Adding the Next Test Date Time e Use the list view to ensure that all active patients have a next test date GO BACK TO MAIN PAGE 3 14 Safety Check List for Adding Editing Patient s Details e When adding a new patient the user should perform a search to ensure the patient s details have not been previously entered e Ensure all patient data including all data entered via any of the tabs on the patient screen has been entered and checked for correctness Attention should be paid to the last name first name unit number and date of birth so that the patient can be uniquely identified every time e Ensure all patient procedures that are entered into the system have been checked for correctness e Ensure all patient events that are entered into the system have been check
157. software maintenance fees these upgrades are usually free 7 The customer is expected to keep abreast of key changes and urgent issues in the product and documentation by visiting the webpage http www 4s DAWN com DAWNSafetyNotices htm weekly To this end the customer must inform 4S of changes to lead contact personnel to ensure that communication is not missed 8 The customer shall review update the settings such as questionnaires and operation of the software on any change to best practise or new advice from drug manufacturers or other relevant bodies 9 The customer should notify 4S immediately if they notice any anomalies within the data or experience anything within the system that could potentially cause a mishap FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 LSC 5 Overview of Novel Oral Anticoagulants Module Features of software to support monitoring of anticoagulation with new oral anticoagulant agents non vitamin K antagonists include Non VKA list view for easy management of scheduled reviews Integrated non VKA history and warfarin treatment records within the patient record structured questionnaire approach to check for contraindications interactions risks Help to follow the recommended prescribing guidelines Powerful reporting o
158. sonal settinas FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 26 1 Export Screen Polar DataExchangdggm Table to export ACbrand bul Fite O OS Not selected For export Selected For export Taro LI5A warFarin USA Generic Warfarin Sinthrome Sinthrome Dindeyan Dindevan Marevan Marevarn Download selected data 9 26 2 Import Screen Polar DataExchange Please give the File to import Browse FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 27 Setting up Printing User Guide If you wish to print from DAWN manually from a patient record no setting up is required DAWN will simply use your internet explorer page settings You may wish to remove the header footer and margins as required DAWN allows you to automate the generation of messages in response to certain events such as authorising a dose scheduling a test or rescheduling a non attender For example you might configure DAWN AC to print a dosing instruction automatically when you accept a patient s dose Depending on certain settings and preferences each message can be sent to a printer faxed emailed or forwarded to the Message Center for telephoning To enable automatic and bulk messaging you must to create a Print Station in DAWN and associate this Print Station with your org
159. t Inadequate C e LMWHdrug 8 O Check that all Gli echt Interruptions t e Acbrand he lanauacde comuption Th CessationReason increase check Language r S Read the Sabe egent B salar FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 CH 9 10 1 List of Languages a Search for Name 4 CodeName OO E SE A bere Ce TERME FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 10 2 Adding a New Language Language New record Name 5 7 Codename Orderhr lille de I Click here an the CK button Save 9 11 Adding Editing a Message Template Letters and forms can be configured within the DAWN system These need to be tested thoroughly if edited or added The support team at DAWN can configure message templates for you if these are needed Please test any new amended message templates carefully before using with real patient data FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual oct Version 1 0 14 06 2013 LicenseAgreement license Max amp ctivePatientCount Frontpage Normal Tables Lookup tables Reports 5 Management Clinic View settings i MessageTemplate MessageEvent MailMerge E Printing Reports Parameter Report amp Polar Reporting 6 Audi
160. t amp security DawnInterface B system CodedComment 137 Fou arae coment logged on ar Support 45 with user proble Tap Grade gt DAWN Es T FRAMEWORK P Anticoagulati Patient view C Add edit or dose a patient List view Daily routines Attendance and nan attendance Diary Consult the diary Message center Manage messages and pass messages by phone Reports Custom reports Settings Modify your personal settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 11 1 List of Message Templates MessageTemplate record 1 50 105 gt Part Site Specific Style Settings n i Frenchay Dose Letter pm cPart Full next test day name and date xi cPart First 2 lines of current dose xi cPart dose change tag x Part HTML Style Sheet compact 1 Name tart site Specific Style Settings RA Notes VW PrintablePatientMessage 1 MallMergeType PrinterPaperType Mone selected RA KN DIV 4margin leFE 15mm pagetable Jwidth 183mm height 37mm margin Eap 47mm Jefttable width 8 1mm righEEable Jwidkh 101mm address padding left 8mm heighE 74mm vertical align bap Font Family arial helvetica sans serif font size 12pt hosno height mm vertical align center Fant Family arial helvetica sans serif font size 12pt nhsnao
161. t Plans for selected z Search for LastWame Ir f FirstName Unitho National Ma Dateofbirth Status At ESSERE EEN We Unit 01 01 1922 1801 Paremil Rd gt ES Sta Lisa 54657565 Bransty Reading EE Ferguson Stacey L 2345345345 1234567 05 06 1993 12 Earls Court breansty Reading D E amp Pearson Paul l4 213344 01 01 1995 12 Chatwarkh Road West Reading D EE Fieldimg Mina 64 6785674 23 05 1945 P Stellar Steven ZU 457456 01 01 1939 EE Pye Delia bb 2344 pra E amp vetanother test 43 464646 Eos ly 01 Burnt houses high road bransty cumbria ES induction Patient os 8 Stevenson Lisa 87 46706478 on EE Pye Delia 66 76543 E amp induction test yrr5757575 ZE tir test 98798797 25 Henley Jason 3457567 EE interval test 4567568 back to detailed Non VKA workflow page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 KM 10 1 1 New Patient Wizard Screen New Patient Wizard New record i i Last name Ethnic origin Mane selected First name Primary language None selected Sex LA kd ome phone Title e Adde Mobile phone Date of birth Geer Age i cl the Work phone Hospital number A National No Email address Messaging method Address 1 Address Z High Town Lounty au will nee
162. t ar dose a patient List view Daily routines Attendance and non attendance Diary gt Consult the diary Message center Manage messages and pass messages br amp GeneralLookupCategory Em Reports Team Custom reports Lookup tables Reports A i Settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 171 9 20 1 List of Wards orsanisation Description nUse E morside Hospital O ES FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 172 9 20 2 New Ward Form Organisation Description Treatment plans px fill need to save this new record before y De A Ward name can be E InUse Ge E J l L L LI E 9 21 Adding a New Patient Group Optional Patient groups are used to group together a subset of patients for use in reporting list views research purposes etc Patient groups are not a mandatory section to be filled in within DAWN FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual oct Version 1 0 14 06 2013 Licensesgreement License _MaxdctivePatientCoLnint Frontpage Normal Tables amp HealthAuthority Organisation e Ward HCProFessianal Clinic Parientaroup LoginL
163. t your system administrator If this occurs you can close down all internet screens and try bringing up DAWN again to log in If you then unsuccessfully try to log into DAWN another two times which totals 5 attempts altogether then your user account will become locked and another user will need to log into DAWN to unlock it If all users are unable to log into the DAWN system there may be an issue with the DAWN system itself Please contact your IT department if this occurs FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 2 FADEV lini Version 1 0 Logging In Active Directory Support DAWN supports Active Directory Login This means users who have a network login can store this ID in DAWN When they access the application if DAWN recognises their network ID it automatically logs them in without prompting them to type a DAWN specific user ID and password To enable Active Directory Support To enable Active Directory Support you need to perform the following steps 1 Enable Active Directory support in DAWN 2 Update each user s Healthcare Professional Account record with their Network ID 3 Disable anonymous access to the DAWN web site in Internet Information Services to ensure that users connect to the web server with their network ID and not with the default Internet Guest Account Enabling Active Directory Support in DAWN 1 Press F5 to display the System
164. tPlan AllowAdmitDischargeTreatmentPlan AllowDeleteTreatmentPlan AllowEditPatientTherapyPhase x x dioe ig None selected Treatment AllowSchedule Treatment High AllowUnSchedule Treatment High AllowEnter ndAccept INR High AllowDNATreatment High AllowTestFailedTreatment Hight AllowAcceptDose High AllowAuthorise High High E AllowAuthnriseManual BridgingTreatment AllowResetTreatment AllowCustomizedWeekPatterns Fisit AllowEdit isit Allow Schedule isit AllowlnscheduleYisit AllowDHA Visil AllowCloseYisit AllowDeleteYisit Patient interventions AllowEditPatientintervention M None selected a AllowAddPatientintervention None selected FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 179 14 06 2013 lAccess to parts of the application AllowViewMenu AllowReports AllowEditReports AllowMessageCenter AllowClinic iew AllowtlinicDiary ShowStatisticsOnBackPage Admin functions AllowViewAll rganisations AllowUsermManagement AllowMaintainUserProfiles 4AllowMaintainDosingEngine Tables AllowMaintainSystemT ables AllowMaintainMedicalLookupTables AllowMaintain rganisationT ables AllowSystemTools AllowYiewAuditTables AllowMonitorScreens e Slide 5110151510115 Application Area specific permissions ApplicationArea Allow Access RE 3 Anticoagulation x Healthcare professionals in this pro
165. tab for later completion x e Y E L D Personal Treatment plang Questionnaires Test Results i P QuestionnaireType Za Rivaroxaban Follow Up 06 06 2013 11 00 ty Rivaroxaban Candidate 30 05 2013 11 15 GFR 68 mL min Dose 20 mg once daily back to Complete a Follow up page F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 back to Detailed Workflow page back to Starting a Non VKA Treatment Plan page 6 3 2 Complete a Follow up Non VKA The Rivaroxaban Follow up Questionnaire will display details from the patient s treatment plan as shown lt is not possible to schedule a Follow up Questionnaire unless an active Rivaroxaban treatment plan has been set Rivaroxaban Follow Up Patient Name Horace Balloon Date of completion 31 05 2013 16 00 31 05 2013 E at 16 00 24hr format HB Please check this appointment is made in your clinic diary or hospital administration system NHS Number to be completed at NOAC Clinic M Unit No 12045204 Status Scheduled Therapeutic Indication Atrial fibrillation nonvalvular NB Remember to schedule a follow up questionnaire for this patient 5 months after the Rivaroxaban treatment plan is activated The questions cover compliance issues patient questions and reasons for compliance issues adverse events o renal function including a calculator for Cockcroft Gault estimate of Cr
166. the DAWN AC system should be checked carefully for completeness and accuracy by a suitably qualified healthcare professional before the patient is instructed For a new oral anticoagulant drug settings are added to the following tables Anticoagulant Regime Qualifying Risk Factors Therapeutic Indications Interacting Drugs Specific Risks Permitted Regimes Non VKA Dose Questionnaire Settings General Lookup Category Settings mandatory settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 16 1 Anticoagulant for non VKA COPY An Anticoagulant will be set for each non VKA but tablet pill size settings are not required Lookup tables C3 Anticoagulation Tables TargetRange INE e Regime Induction Algorithm 16 2 Regime for non VKA COPY Regime settings are required for each Dabigatran or other non VKA dose to be used in DAWN AC Regime O OOOO Acenocoumarol Whole Tablets in Mg Daily Avg Daily Active B Dabigatran 110 mg twice daily Daily Active Dabigatran 150 mg twice daily Daily Active Dabigatran 150mg once daily Daily Active Dabigatran 220mg once daily Daily Active Dabigatran 75mg once daily Daily Active Description Dabigatran 110 mg twice daily CodeName DAB110TD Status Active Anticoagulant Dabigatran Brand None selected DailyWeekly Daily DoseUnits Mg MinimumTabletPart Half a tablet Tablet 1 None selected I
167. tings for non VKA leeeeeeeeeeee eene nennen nnne 240 Part XVI Settings for Novel Oral Anticoagulants 4S copy 243 Q1 Anticoagulant for non VKA EREECHEN 244 2 Regime for non VKA COP Y cacicseei aoc oxo ao aree ac quoa aee oSuE Ene caua uuu a Sa ou us aves Savoy ode uuu DE c iaki 244 3 Qualifying Risk Factors for non VKA COPY eeseeeeeeeseeeen enne nennen nnn nnn 244 4 Therapeutic indications COP Y ooi ei idee di 245 5 Interacting drugs Tor non VKA COP Viena 246 Specific Risks for nori VKA COP Y cate weds scus dd 246 T Permitted Regimes EES 247 8 NOM VKA DOSS GORY t M 247 9 Questionnaire settings for non VKA COPY seeseseeeenene nenne hen nne nn nennen 248 10 General Lookup Category settings for non VKA COPY leere eene 248 Index 250 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 o Foreword 1 Novel Oral Anticoagulants Module User Manual I DAV CLINICAL SOFTWARE The Novel Oral Anticoagulants User Manual provides the steps and workflows needed to add edit and manage patients on novel oral anticoagulants eg Rivaroxaban within the DAWN system safely and effectively DAWN is registered trademark of 4S Information Systems Ltd and represents a new era in software where the ad
168. tionReason New recor ApplicationArea Anticoagulation Name 48 0 OrderNr You must specify a 9 14 Coded Comments You can define short codes for frequently used comments for example nbb for no bleeding or bruising The CodedCommentPrefix system setting is used to define a prefix by default that identifies the text you type in any notes field as a short code As such you could type nbb anywhere in a Patient Note Treatment Note or Quick Note FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 147 and this would automatically expand to say no bleeding or bruising when the note is saved To define coded comments e Press F5 to display the system menu e Choose Management Coded Comments to show the coded comments list this is empty to start with Frontpage Patient List view Message Center Reports Normal Tables Lookup tables Reports Management Clinic View settings MessageManagement Printing Reports Audit amp security System CodedComment CustomModule e Choose the New button to add a coded comment CodedComment ShortCode FullComment Y E Patient called and left a messagel e Save your Comment e n your patient notes screen place your code i e pc Graph D ene M E 3 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version
169. tment plan is stopped the record can be marked as Inactive or Deceased and will not affect your licensing on DAWN it can remain on your database for audit purposes If you wish to remove a patient record that you have added in error you must first 1 Stop any treatment FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 EH 2 Delete any all treatment plan s 3 Mark the patient as inactive A Delete button is then displayed so you can delete the patient record FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 ECH 11 Viewing Patient History Your patient may have several consecutive treatment plan records and only one of these may be active for their current anticoagulation Blue Brian 04 04 1946 342523555 Pref clinic NOAC Clinic Big Hospital T Phone 015395 63091 home B Recurrent DVT _ Non VKA 03 01 2013 Indefinite Hivaroxaban 20 mg Once Daily Ee T Treatment plans AC Anticoaqgutauun Start date 03 01 2013 Duration Indefinite Target range Hon VKA Anticoaqulant Rivaroxaban 20 mg Once Daily Referring GP Central Surgery Bloggs Frank Consultant Big Hospital Stornaway Deirdre Start date 21 12 2012 Duration Treatment stopped Stopped at 03 01 2013 11 42 Target range Non WKA Anticoaqulant Rivaroxaban 15
170. tor Patent vem a Kl Nod edtor dose s patens Leet v cu d DV pees Attendance and non attendance Char Corel the Gar Rem center Hp meses an pais meses by phone Reporta Custom reports Settings Mod r your personal settings Currie losa Tor pring Office ES FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 8 10 Message Center Wio to call Alfie Normal 12 12 1943 Patent 1 Pat Pattern 12 12 1966 Patient i ad Flintstone 12 12 1978 Patient 1 redi eee 1 1 det 1 Patient 1 Patent 1 Patient 2 Busy Bee Area Hospital Dr Click to see details af call required Click to see full patient details nt screen Se 29 12 2008 15 50 Phone call SOLES 15 Phone cal FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 107 9 Configuring your system 9 1 A Adding Editing Allergies If you need to add an allergy for a patient that does not exist in the standard list new allergies can be added here LicenseAgreement license Max amp ctivePatient i Look Frontpage n Normal Tables Lookup tables Anticoagulation Tables e Allergy Bloodgroup Diagnosis Drug Druginteraction 9 EthnicOrigin e Event HCProfessioanalTvpe JournalltemType O LetterTemplate amp OrganisationT pe Procedure
171. treatment plan for the new dosage without a setting in this table i The settings here are critical to how your DAWN system operates and any changes deletions additions are likely to affect the anticoagulant dosing of past present or future patients ALL changes to settings should be tested thoroughly on a test database FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 before applying changes in your production database Permitted Regimes Other validation checks are made on first activation of a treatment plan and on saving an Initiation Questionnaire on the settings stating which regimes ie dose of Rivaroxaban for example are appropriate for which primary diagnosis or therapeutic indication Additional regimes can be added to this table as appropriate Permitted Regimes FES Rivaroxaban RecPE Recurrent PE Y Rivaroxaban 15 mg Twice Daily z Normal Dose Day1 21 Ey Rivaroxaban Recht Recurrent PE Rivaroxaban 15 mg Once Daily z A reduction of the dose from 20mg ES Y Rivaroxaban RecPE Recurrent PE v Rivaroxaban 20 mg Once Daily Normal Dose Day 22 onwards The Clinical Advice is displayed on the Initiation Questionnaire screen as below and the Order number is relevant for display on the questionnaire screen Dosing regime Rivaroxaban 15 mg Twice Daily Hivaroxaban 15 mg Once Daily Hivaroxaban 20 mg Once Daily Advice Mormal Dose
172. ts have been thoroughly tested before using them in a live situation e Check that all the required reports have been defined and are available for use e For each report check that the correct fields are included in the report e For each report check that the correct data is being generated GO BACK TO MAIN PAGE Safety Check List for Questionnaire Definitions If you have purchased and are using the questionnaire module e Ensure all new altered and imported questionnaire definitions have been set up and checked for correctness For each questionnaire definition o Ensure the questionnaire definition has been correctly defined with the correct name and code and has been assigned to the FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 LSK correct department o Ensure all the options calculations have been defined correctly e Ensure all new altered and imported questionnaire definition have been thoroughly tested in your practice system before using them in a live situation GO BACK TO MAIN PAGE 3 10 Safety Check List for Data and Operational Integrity Ensure you have written procedures and physical arrangements for e Checking all user profiles are properly set and are checked to be working e Checking that the system settings are appropriate to the environment and method of working and to optimise system performance within your organisation e T
173. ttl data T O ReferenceRange TestGroup z e TherapyTemplate Trial i OQuestiannai See CHADS score NB renaming or deletion of an entry for General Lookup or General Lookup Category may cause loss of information in any patient questionnaire not completed or unlocked for editing back to Settings for New Oral Anticoagulants page FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 16 Settings for Novel Oral Anticoagulants 4S copy Your System Manager can access settings for Dabigatran and other anticoagulants in the System menu gt Lookup tables a 45 DAWN Clinical Software amp Internet Applications Window LicenseAgreement Welcome License MaxActivePatientCoul Frontpage Normal Tables TargetRange INR Anticoagulant e Regime Induction Algorithm ResultRange INR ACTestAlias Qualifying Risk Factors Therapeutic Indications Interacting Drugs amp Specific Risks Permitted Regimes amp Non VKA Dose Ouestionnaire Settings The settings here are critical to how your DAWN AC system operates and any changes deletions additions are likely to affect the anticoagulant dosing of past present or future patients ALL changes to settings should be tested thoroughly on a test database before applying changes in your production database ALL outputs like letters e mails from
174. u select filters on the left to refine the list remember to remove the filters to check the full list NaMgating List Views back to Workflows in DAWN page Navigating List Views Click the List view Daily routines button on the front screen to open the List View screen FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 227 Ai Wed 01 06 2011 DAWN J 9 Version 7 9 14 1281 Rheumatology Patient view C Add edit or dose a patient List view Daily routines Attendance and non attendance Diary 3 Consult the diary Message center Manage messages and pass messages by phone ba Reports custom reports Settings Modify your personal settings The List View screen consists of a number of tabs Each tab contains a different List View specifically designed to support key activities such as reviewing test results or following up non attenders Each individual List View comprises two panes e The control pane e The list pane The list pane is the right hand pane and lists all the patients or tests meeting the selected criteria The control pane is the left hand pane and contains drop down lists of additional filters that allow you to further control which patients or tests are displayed F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 unfiltered I Schedule
175. ual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Eh 9 9 2 Adding a New WarnLevel WarnLevel New record WarnGroup Name WarnLevel Warningimage AlwaysWarn O InUse TestChar alueOption SOK Se A Se save 9 10 Adding Editing Languages If you need to add a language for a patient that does not exist in the standard list new languages can be added here F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Frontpage rou are cuente logged an ap itching George Lor eer er proie Zon Ti ap Gr Grace Normal Tables 5 Lookup tables Anticoagulation Tables D AW N Allergy _ Bloodaroup Anticoagulatior Diagnosis e Drug gt Druginteraction Abba Patient e EthnicOrigin add edit or i Event HCProFessianalTvpe List view amp JournalltemType Attendance LetterTemplate e Organisation ype Diary amp Procedure Consult the Risk amp Severity Message i Severity Type Manage mes O RiskClass amp Disease area Reports DiagnosisGroup Custom rep Diagnosisstage Discipline Settings ip MeetingTvpe E CrugDoseUnits E DrugDburationlIniEs CrugMedium amp CrugVolumeUnits Frequency e War evel IT Bu logging op conditions oF 1 Current location For pril i VisitType InterventionTimeslo
176. ure Anticoaqulati Patient view e Add edit or dose a patient List view Daily routines Attendance and nan attendance Diary Consult the diary Fisk aor Message center Sech y Manage Messages and pass messages by phone Severity Type O RiskClass ia Reports Application rea ER Custom reports amp Diagnosisaroup DiagnosisStage Discipline Meetingl ype D DrugDoseUnits i Current location For printing Select a location ze CrugDurationUnits DrugMedium i Ln CENE CrugVolumeUnits No of Active Patients B Patieri Settings Modify your personal settings FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 9 18 1 List of Organisation Types TbescriptionMulti E Cro rs ns Si GP Practice P Practices JE Y Laboratory JLatozgores PS ursingHome fvursingHomes PS Y Software vendor Bauere vendors JS 1111 d FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 9 18 2 Adding a New Organisation Type InUse pa suste stat bur see mua ql be ar E COM a a mit E LUPUIOUE ERSE ie RE Dios must d EE AE ti Re IM arder OK AA AA Lo Gw e 9 19 Adding a New Organisation Different organisations can be set up within the system so that he
177. w to e Find patients overdue for review e Record any necessary action Generate a letter or e mail to the non attending patient See the following sections for more information Using the list view to find patients who are overdue for follow up Changing the treatment plan Printing letters from DAWN using pre configured templates FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual oct Version 1 0 14 06 2013 14 Running Reports amp i KI Fi Fri 31 08 2012 DAW N A NEN l 9 Version 7 3 25 1283 Anticoagulation 7 Patient view ei az Add edit or dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary SS Message center Manage messages and pass messages by phone Modify your personal settings Choose the report from the dropdown menu and select any parameters as required before choosing Show report TEE Patients by Current Drug Count Drag name 3 DEOXYCYCLINE ACETAZOLANIDE d ACTOFAN ACTRON EFF TABLETS ADALAT ADIFAX ALKA SELTZER ALLOPURINOL r Department Rheumatology Shaw report Cownload az XML Downlaad az Text Email addrezz kd Rheumatology Therapy Reference Range Phase TETTE DMARD Maethatrexate Hydroxyzhlarequina z weakly monitoring 1 Hydroxychloroq Data may be extract
178. will use the correct printer paper type when printing this message template e Choose Save FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 Message Template record 1 50 107 ben Part Site Specific Style Settings Frenchay Dose Letter cPart Full next test day name and date cPart First 2 lines af current dose cPart dose change flag Part HTML Style Sheet compact Name ParE Site Specific Style Settings RA Notes Vi 101950150 PrintablePatientMessage 1 MailMergeType DescriptionTemplate at era V PrinterPaperType BA KN DIV margin left 15mm pagekable width 1 amp 3mm height 237mm marui Plain Paper Jefttable width 8 1mm Fightbable width 101mm address padding left 8mm heighk 74mm vertig etica sans serifiFont size 12pt hosna height 7mm vertical align center Font F ont size 12pt nhsna height 5mm vertical align center Font F ont size 10pt Jastname Jheight Smm vertical align Center To Firstname height Smm wertical align center Fo dob fheight 11mm vertical align topsfont Famil Hhistorycomment height 4mm vertical align cen ns serifiFont size Bpk titleheight eight 10mm vertical align center Fa sriF Fank size amp pt Date width 10mm Font Farilv arial helvetic INR midth 8mm Font Family arial helvetica ll
179. ype e LetterTemplate OrganisationT ype Procedure e Risk Severity SeverityType RiskClass amp Application rea Diagnosisaroup DiagnosisStage Welcome Fou dre currantiy fogged on ar Supon 35 w wer profe Top Grace AE o re FADEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 LAS CLINICAL 5 aAnticaatr Patient view L Add edit ar dose a patient List view Daily routines Attendance and non attendance Diary Consult the diary Message center Manage Messages and pass messages by pt Reports Custom reports Settings 14 06 2013 Eh 9 2 1 List of Blood Groups BloodGroup Description Date Y postive JP FADEV Clinical Framew ork E Manual Non V KA DAWN Non VKA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 KR 9 2 2 Adding a Blood Group BloodGroup New record Description E 4 blood group InUse xi m lon can be 9 3 Adding Editing Diagnoses If you need to add a diagnosis for a patient that does not exist in the standard list new diagnoses can be added here F DEV Clinical Framew ork E Manual Non V KA DAWN Non V KA Rivaroxaban User Manual pdf Version 1 0 14 06 2013 CH icenseAgreemernt License MaxActivePatientlount Frontpage Normal Tables Lookup tables 6 Anticoagulation Tables e

Download Pdf Manuals

image

Related Search

Related Contents

Radio KDS K-7XII  Philips HEPA-filter AC4900  VisionTek 900685 AMD Radeon R7 250 1GB graphics card  Manual SKV - Chemlin Pumps & Valves Pvt. Ltd.  

Copyright © All rights reserved.
Failed to retrieve file